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Today, few studies have research what kind of pain management is given to Norwegian people 
with dementia (PWD) who lives at home. With a growing population of PWD, it is important 
to understand the issues that PWD experiences. Pain is a common co-morbidity for PWD due 
to the aging prossess. Yet we have little information on how many PWD uses analgesics in 
Norway and if dementia symptoms and pain effect the analgesic use.  
 
Aim 
The primary outcome of the thesis is to find out how many home-dwelling people with dementia 
uses analgesics, what type of analgesics they use and if there is an association to cognitive 
status. The second outcome for the study is to check whether or not there is a correlation 
between analgesic use and behavioral and psychological symptoms in dementia (BPSD).  
 
Methods 
The thesis is a cross-sectional observation study. The data material was provided from the 
LIVE@HOME.path trial, currently running in three Norwegian cities. The data material used 
is from the baseline data collection in 2019. The baseline was conducted as a two separate 
interviews, one for the person with dementia and one for their informal caretaker. The methods 
included in this thesis are MMSE, NPI, CMAI, CDSS, MOBID-2, EQ-5D-5L and a medicine 
list from person with dementia.  
 
Results 
The result showed that 19.6% of the population uses analgesic regularly. With on-demand use,  
a total of 32.1% of the study population used analgesics regularly and/or on-demand. The most 
common analgesic used was paracetamol, while few participants used opioids and NSAIDs. 
The analyses between analgesic use and cognitive function or for BPSD were not significant.  
 
Conclusion  
Around 20% of home-dwelling PWD uses analgesics. Only half of the people with pain used 
analgesics regularly. However, is was positive that few participants had severe pain and few 
people used opioids and NSAIDs. There was not found an association between analgesic use 




1. Introduction and background 
1.1 Epidemiology of dementia 
Dementia is among the top 10 diseases that people die of across the world (1). Most patients 
are elderly, with higher age increasing the risk of developing dementia. For people aged 60 
years and over, it estimated that around 6.9% of people in Western Europe have dementia. The 
prevalence is anticipated to rise in the next decades as a consequence of an aging population (2, 
3).  
 
In 2020, the Norwegian Advisory Unit on Ageing and Health (Ageing and Health) released a 
national prevalence report for dementia, ordered by the Norwegian Directorate of Health. It was 
the first report that standardized the estimates of prevalence, using the Norwegian population 
as the reference group. Gjøra et. al. reported that as of 2020, there were around 101 000 persons 
in Norway living with dementia (4).  
 
The researchers also report that there will be an increase of people with dementia in Norway 
over the next decades. The main reason is the changing demographics in Norway. As of 2020, 
there are almost 670 000 people in Norway that are 70 years or more (5). By the year 2050, this 
age group is expected to increase to around 1.25 million people (6). The growth is especially 
prominent among the group of people over 80 years, which is expected to triple in size, while 
the number of people over 90 years will increase almost five times by 2060 (7). Because of the 
increase within these age groups, a larger share of the population will be elderly people. This 








Figure 1.2 People aged 70-79, 80-89 and 90-99 years in Norway from 2005 to 2050 
(estimates) (5, 6). 
 
Figure 1.1 show that the density increases for the older age groups from 2020 to 2050. The 
difference is especially prominent for the oldest age groups. Figure 1.2 describes the estimated 
population growth among the age groups 70-79, 80-89 and 90-99 years old. The age group 70-
79 is under a strong growth from 2015, which is expected to lead to an increased population for 
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The change in demographics can lead to a growing population living with dementia. Dementia 
is a common syndrome for elderly people, and the prevalence increases with age. 
Approximately 33% of people aged 80 years and older, and 48% aged 90+ had dementia in 
Norway in 2019 (4). With an increase of elderly people over the next decades, it is expected 
that by 2050 around 235 000 people in Norway will live with the syndrome (4).  
 
The development can presents a range of issues within dementia care. The most pressing issues 
would be the socioeconomical costs connected to health care and assisted living, and building 
enough nursing homes for people who cannot live at home anymore (4). Dementia is a major 
cause of disability and loss of independence across the world. Because the ability to live 
independently decreases with the progression of the syndrome, dementia is a leading cause of 
nursing home admission (8). A total of 83.4% of residents in Norwegian nursing homes have 
dementia (9). A relatively high proportion of the total societal costs caused by dementia are 
attributable to public health and care services (e.g. institutionalized care, home nursing, and 
pharmacological treatment), which is estimated to be 35.8 billion NOK (10). In total, the 
societal costs for 2019 including disease burden, health care cost and loss of productivity have 
been estimated to be around 96 billion NOK, which is higher than the costs attributable to 
instance heart failure (48 billion NOK) or obesity (68 billion NOK) (10). In addition to the 
societal costs, PWD who wants to remain living at home could experience loss and reduced 
quality of life upon admission to nursing home care. A study from Norway demonstratetd a 
significantly higher quality of life for PWD living at home compared to PWD living in nursing 
homes, even when stratifying for dementia severity (11). Therefore, the home-based dementia 
care at home should be optimized in order to handle the demographic changes.  
 
1.2 Aging and dementia  
It is important to understand the complex age-related issues, such as physiological changes, 
frailty, comorbidity and polypharmacy in order to understand the issues that can occur for 
people with dementia.  
  
Physiological changes in elderly people  
The majority of people with dementia are considered to be elderly (2). Old age is not defined 
by specific biomarkers yet, but the group termed older adults is generally perceived to include 
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those aged 65 years or more. As people reaches old age, many experiences negative age-related 
physiological changes (3, 12). 
 
Elderly people go through a process where the organs and tissues gradually loses their 
functions. Some age-related physiological changes include slowing of the gastrointestinal 
systems, reduced hepatic and renal function and changing fat distribution. These changes can 
affect the pharmacokinetics of the body, which can make elderly people more vulnerable to 
developing diseases and having adverse effects from pharmaceutical treatment. Elderly people 
can have multiple diseases, whuch require pharmacological treatment, while at the same time 
they become less tolerant to treatment, creating complex issues for healthcare professionals 
(12). The aging prosses is highly linked to frailty, a condition where multiple physiological 
systems decline and the person has little reserves to handle additional stress. These situations 
can be starting a new drug or changing environments, for instance being hospitalized. It presents 
an array of difficult challenges to physicians and other health workers, because of the reduced 
ability to handle a possible deterioration (13).  
 
Comorbidity is the presence of at least two more condition in a person at the same time (14). It 
is very common among elderly people and people with dementia. Studies have showed that age 
is an important factor for co-morbidities, with a large study from Scotland showing that the 
prevalence increased from 64.9% for people aged 65-84 years, to over 80% for people ≥ 85 
years (15). Since dementia is highly linked to advanced age, the prevalence of comorbidity is 
also high for this demographic. A large study from Spain showed that almost 90% of people 
with dementia had comorbidities, while another large study from Canada showed a prevalence 
of over 90% (16, 17). The most frequent comorbidities of dementia are cerebrovascular disease, 
diabetes and conditions related to pain (16, 17). Pain in dementia will be described more later 
in the introduction.  
 
Increasing age can lead to diseases, including dementia, polypharmacy and is associated with 
pharmacological and changes is how pharmacological treatment affects the individual (3, 12). 
Because co-morbidity is so prevalent among elderly people and PWD, many people uses 
multiple medications. Polypharmacy is commonly defined as the concomitant use of ≥ 5 daily 
medicines (18). A Swedish register-based study from 2018 showed that people ≥ 65 years old 
used 4.6 medicines on average, and that 44% had polypharmacy (19). The numbers are similar 
for other studies conducted in Western countries, with estimated prevalence of polypharmacy 
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ranging from 29-65% using over 5 medicines (20, 21). Polypharmacy can increase the risks of 
adverse effects and interactions, and elderly people are especially vulnerable because of age-
related physiological changes (12, 18). This makes treatment of other conditions more 
complicated.   
 
1.3 Dementia – definition and etiology  
Dementia is among the top 10 diseases across the world and is the only disease on the list that 
cannot be prevented, treated or slowed down in a significant way (22). Norway uses the 
International Statistical Classification of Disease and Health Related Problems (ICD-10) from 
the World Health Organisation (WHO) to report diagnoses  to the Norwegian Patient Registry 
and to define diseases and disorders (23). According to the updated ICD-11, which will 
eventually replace ICD-10, dementia is defined as an acquired brain syndrome that causes a 
progressive decline of cognitive functions from previous levels. For a person to be diagnosed 
with dementia, the individual must have a lasting impairment within two or more cognitive 
domains. These cognitive domains are memory and learning, attention, language, social 
cognition and judgement, visuospatial abilities, executive functions and psychomotor speed. In 
addition, dementia is excluded if the decline stems from altered mental status, disturbed 
consciousness, delirium, substance use or other mental and behavioural conditions that affect 
the brain. Dementia is not a part of normal aging and significantly interferes with normal 
activities in daily life and independence (24).  
 
There are different subtypes of dementia depending on etiology, which cognitive domain is 
affected and the severity of symptoms (25, p. 591). However many of the symptoms are the 
same for the different subtypes and the people who are affected deal with similar problems in 
their lives (25). There are multiple causes for the syndrome which generally can be divided into 
neurodegenerative and non-neurodegenerative origin. Neurodegenerative dementia is caused 
by irreversible damages to the neurons in the brain. Non-neurodegenerative dementia is caused 
by other factors, such as cerebrovascular disease, traumatic brain injuries, chronic substance 
abuse etc. Physicians can detect characteristic changes in the brain through a magnetic 
resonance imaging (MRI) to diagnose dementia subtypes (26). It can be challenging to diagnose 
people with a subtype, since the symptoms can be similar and people can be  diagnosed with 
multiple subtypes (26). However, it is useful to understand the common subtypes because we 
can then understand the symptoms better. Here is a short presentation of the most common 




Alzheimer´s disease (AD) is the most common type of neurodegenerative dementia (26). 
According to the Norwegian prevalence report by Gjøra et.al., around 57% of PWD in Norway 
have AD (4). AD is a neurodegenerative subtype and is characterized by a slow and gradual 
accumulation of amyloid plaques and intraneural neurofibrillary tangles (NFT) in the brain. The 
amyloid plaques and NFT damages the neurons in the brain and disrupt neuronal function (27). 
Typical symptoms include slowly progressing memory loss early on in the disease course, in 
addition to other signs such as irritability, apathy and low mood. As the disease progresses, the 
patient can begin showing behavioural, visuospatial and language disturbances are frequent. In 
addition, their judgment might become impaired and confusion and disorientation is common 
(26, 28). 
 
Vascular dementia (VD) is the second most common dementia in Norway, around 10% of those 
with dementia according to Gjøra et. al. (4). Vascular dementia is triggered by a cerebrovascular 
injury in the brain, such as ischemic or hemorrhoidal stroke, and is classified as a non-
neurodegenerative subtype. There are several modifiable risk factors which can lead to the 
person developing a vascular cognitive impairment, such as hypertension, hypercholesteremia, 
diabetes and smoking. In addition, risk factors for stroke such as coronary heart disease, atrial 
fibrillation and myocardial infarct also increases the probability of a vascular cognitive 
impairment (26). Unlike AD, which causes a gradual and progressive cognitive decline (usually 
over many years), people with vascular dementia can have an abrupt cognitive decline 
following a stroke. Alternatively, the cognitive decline can appear more gradually and plateau 
within a few weeks to months after the stroke. The cognitive decline manifests within a 
relatively  short time period after a cerebrovascular incident and symptoms can be slow speed, 
subtle speech changes, memory loss and apathy, depending on the region affected and the 
severity of the stroke  (26).  
 
Mixed dementia, mostly with parallel AD and VD processes, is thought to be more common 
among those aged ≥ 85 years (27). Around 9% of PWD in Norway have a mixed dementia 
diagnosis according to the prevalence report from Gjøra et. al. (4). The diagnosis can be set if 
a person has signs of AD and later on experiences a stroke that worsens the cognitive decline. 




Dementia with Lewy Bodies (DLB) and Parkinson’s disease with Dementia (PD) are 
neurodegenerative dementias with similar symptoms. It is estimated that around 4% of PWD 
are diagnosed with these subtypes in Norway according to the Norwegian prevalence report 
(4). However, DLB and PD are probably underdiagnosed among PWD (29). A study from UK 
showed that 4.6% of PWD had DLB alone, while a meta-study estimated around 3.5% of PWD 
had PD (30). The cognitive impairment is caused by an accumulation of Lewy bodies, a 
synaptic protein consisting of alpha-synuclein, in neurons (26). Common clinical symptoms for 
DLB are cognitive fluctuations, visual hallucinations and features from parkinsonism (limb 
ridgidity, tremor at rest, slow movements, etc.). Memory loss and spatial difficulties can be less 
prominent compared to other dementia subtypes. In PD has also an accumulation of Lewy 
bodies and similar symptoms are also observed, however the subtype of DLB or PD is 
diagnosed based on time  of onset. If the cognitive symptoms debut at least 1 year after being 
diagnosed with Parkinson’s disease, then the person is diagnosed with PD rather than DLB 
(26).  
 
Frontotemporal dementia (FD) is a group of neurodegenerative dementias that are caused by a 
selective degeneration of the frontal and temporal lobes of the brain. It is estimated that around 
2% of PWD have this subtype according to Gjøra et. al. (4, 26). Symptoms of frontotemporal 
dementia are dependent on which region of the brain is affected. Patients with the behavioural 
variant often shows symptoms such as personality changes, lack of inhibition and loss of 
executive functions. Other types of FP can have progressive aphasia, parkinsonism, frequent 
falls and behavioural changes as prominent symptoms (26).  
  
The cognitive decline and symptoms makes PWD a vulnerable group. The majority of PWD 
are elderly and therefore prone to age-related issues. Dependent on the dementia subtypes, the 
symptoms could make it difficult for PWD to understand and express themselves when 
receiving treatment. This can lead to them having a higher chance of receiving inappropriate 
treatment, and increase the risk of drug-related injuries. Other PWD might not receive treatment 








1.4 Pain in dementia  
Pain is a condition that is often a debilitating and defining feature in different diagnoses. The 
International Association for the Study of Pain (IASP) currently defines pain as “an 
unpleasant sensory and emotional experience associated with, or resembling that associated 
with, actual or potential tissue damage” (33). The definition was revised in 2020, adding the 
line “or resembling that associated with” to include the experiences of people who could not 
verbally articulate their pain, such as people with dementia (33). 
 
Many community-dwelling PWD suffers from pain, but pain prevalence estimates vary 
between different regions and depend on how pain is assessed in different studies. One study 
from the UK (N=488 participants) showed that 45% of PWD had reported pain, while 
caregivers had proxy-rated 59% of PWD to be in pain (34). Another study from Denmark 
(N=321 participants) showed that 33% of PWD reported pain, while caregivers proxy-rated that 
52% of PWD had pain (35). In a small study from Northern Ireland (N=75), 57.3% of PWD 
reported that they had pain on an average day and 36.0% reported pain “right now” while 
caregivers reported that 70.7% of PWD had pain on an average day and  53.3% had pain “right 
now” (36).  
 
Pain is often caused by age-related comorbidities, and the most common causes of chronic pain 
in elderly people are musculoskeletal issues, diabetic and postherpetic neuralgia and chronic 
inflammation of joints (37). These diagnoses and types of pain also affect PWD increasingly 
with advancing age. In addition, PWD commonly experience orofacial pain and neuropathic 
pain from stroke (38-40). Pain is more prevalent among, those who used multiple medicines, 
and are those who are older (37, 40). 
   
Pain assessment in dementia can be difficult because of the cognitive impairment affects PWD. 
For pain treatment to be successful, it must be based on a valid and accurate assessment of the 
pain intensity. Self-reported pain intensity is considered the “gold standard” for pain assessment 
because pain, per definition, is a subjective experience. However, because of the nature of the 
disease, PWD might struggle to express, understand, remember or reflect over their painful 
symptoms and could give unreliable answers. Therefore, it is important to use other assessment 
methods in addition to self-reported assessment in PWD to increase the chance of accurately 
assessing their pain. Other methods that can be used are caregiver rated assessment, 




If pain is not detected and treated among people with dementia, it can lead to a range of negative 
consequences. Persistent pain has been linked to having an accelerated cognitive decline, 
reduced mobility, increased risk of falls, lower quality of life and mental health issues such as 
behavioural and psychological issues (41, 42).  
 
PWD with dementia can display pain through behavioral and psychological symptoms in 
dementia (BPSD) (43). BPSD, also known as neuropsychiatric symptoms, are a range of non-
neurocognitive symptoms and behavioral symptoms amongst people with dementia. These 
symptoms can be agitation, anxiety, depression, irritability, apathy, elation, delusion, 
hallucination, abnormal motor behavioral, disinhibition and changes of sleep or appetite 
pattern. BPSD re chllenging for the individual, their families and caretakes, leading to earlier 
admission to institutions and higher risk of morbidity and distress for the person with dementia 
(43).  A few studies have shown promising results indicating that BPSD may be reduced 
through analgesic treatment (44-46). However, there is still limited evidence for this treatment 
approach and should be researched further (47). 
 
Some PWD can have undetected pain for long periods of time and suffer unnecessarily if we 
are not aware of the signs. Whether or not the painful conditions might affect their mental state 
or their behavioral, it is important to ensure PWD  receive quality care to maintain comfort and 
dignity into old age. The Dementia Plan for 2025, issued by the Ministry of Health and Care 
Services in Norway, states that palliative treatment should be an integrated part of the treatment 
plan from the early stages of dementia (48). The Norwegian national guidelines for dementia 
care also state that healthcare for PWD should ensure individualized palliative care throughout 
the course of dementia. Furthermore, the guidelines strongly recommend that people with 
BPSD should be assessed for pain (49). 
 
1.5 Analgesic treatment in elderly people with dementia 
In this thesis, pain management will only be assessed and described in terms of pharmacological 
treatment with analgesics, although it is important to stress that pain management in practice 
encompasses a much broader approach including consideration of individual and environmental 
factors and non-pharmacological interventions. No specific guidelines exist for the treatment 
of pain in dementia, except general guidelines developed for the elderly population (28). 
Depending on the type, cause, and duration of pain, it is common to follow a stepladder 
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approach inspired by the WHO analgesic ladder, implementing the weaker analgesics first 
(alone or in combination with adjuvant analgesics) and gradually adding stronger analgesics 
until the patient experiences pain relief without detrimental adverse effects (50, 51). In the 
following, the most important analgesic substances and classes will be presented briefly.  
 
 The first-line therapy recommended for PWD is 
paracetamol, also known as acetaminophen (52). The drug 
mechanism is complex and not fully known, but paracetamol 
is a weak inhibitor of prostaglandin synthesis via 
cyclooxygenase (COX) dependent pathways (53). 
Paracetamol has analgesic and antipyretic properties. 
Paracetamol is the preferred first choice particularly in 
elderly people because it has similar analgesic effect as other 
weak analgesics with a more favorable side effect profile and 
few adverse effects in therapeutic doses. However, paracetamol may not alone be sufficient to 
treat severe pain. It can also cause hepatoxic damage in overdoses (54). 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are analgesics with anti-inflammatory 
properties. They work mainly by inhibiting prostaglandin synthesis via the COX enzymes 
(COX-1 and COX-2), thus reducing inflammation and pain. NSAIDs are effective for mild and 
moderate pain, especially with inflammatory causes such as arthritis (55). However, adverse 
effects limit their usefulness in elderly people and PWD. The side effects include 
gastrointestinal ulcers and bleeding, increased cardiovascular risk, and nephrotoxicity, which 
can be life-threatening if left untreated (56). There is little information about regular use of 
NSAIDs for PWD (52). However it is not recommended for elderly people to use NSAIDs over 
time because of age-related changes and comorbidities and high risk of adverse effects (56).   
 
Opioids are a class of potent analgesics that are used to treat moderate to severe pain. Opioid 
analgesics can be classified as weak and strong depending on their relative potency (57). 
Examples of weak opioids are tramadol and codeine, while examples of strong opioids are 
morphine and oxycodone. Opioids act on opioid receptors that are mainly found in the central 
nervous system and peripheral sensory neurons, causing a chain reaction that reduces neural 
transmission to the brain and interferes with the perception of pain. Opioids have several 
frequent side effects, such as nausea, constipation, adverse effects on the central nervous system 
Figure 1.3: The compound paracetamol  
(acetaminophen). Made for this paper.   
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and respiratory depression. For PWD, there is particular concern that  chronic opioid use may 
lead to worsened cognitive function and mental health and increased somnolence (58). Strong 
opioids have become more commonly used among PWD because of easier administration with 
transdermal patches (TDP) (59). However, the evidence for effect in chronic noncancer pain is 
weak and there are safety concerns (52, 60).  
 
1.6 Prevalence of analgesic prescribing in community-dwelling PWD 
Over the recent years, the use of analgesics amongst PWD has generally increased (52). A 
systematic review from 2019 found that community-dwelling PWD used paracetamol more 
frequently than people without dementia. The review also found that PWD were more likely to 
be prescribed stronger analgesics, such as opioids (61). However, the prevalence of opioid 
prescribing varies widely between countries and regions (59).  Fewer PWD used NSAIDs 
overall (61).   
 
The Norwegian national guidelines for dementia care do not include a general guideline for 
analgesic treatment in PWD, but refers to general guidelines for the elderly population. The 
general advises for analgesic use is to start slow and gradually increase doses since elderly 
people may experience pain relief with smaller doses. Furthermore, the physicians should 
reevaluate the benefits of treatment by medication discontinuation (49). A systematic review 
from 2016 showed that many studies  had  endorsed the use of paracetamol or strong opioids in 
smaller doses for PWD, however the evidence-base for remains weak (52, 62).  
 
A non-systematic literature search was conducted to investigate the use of analgesics among 
community-dwelling PWD compared to people without dementia. The search focused on the 
medical subject headings (MeSH) “Dementia”, “Analgesics” and “Pain” in the Pubmed 
database, in addition to free-hand search strategies. After reviewing the results, 6 studies were 
included. The studies had to include both community-dwelling PWD and a comparison group 
of people without dementia. This was a requirement in order to compare prescription rates 
between PWD and age-matched controls. Furthermore, the studies had to include at least one 
analgesic class between opioids, NSAIDS or paracetamol. The characteristics that were 
included were age and MMSE score, if available.   
 
Studies that had data from both nursing home facilities and from community-dwelling people 
where included as long as the data were stratified for both cohorts. Furthermore, studies 
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published before the year 2000 were excluded. Publications that were not written in English or 
a Scandinavian language were also excluded from the literature results.  
 
 19 
Table 1.1 Studies mapping use of analgesics amongst community-dwelling people with or without dementia 
 Pop. Characteristics Tot. analgesic use (%) Paracetamol (%) NSAIDs (%) Opioids 
 Dementia 
N (%); MMSE; 
Age 
No dementia 
N (%); MMSE; 
Age 
D ND p D ND D ND D ND 
Mantyselka et. 
al. (63), 2004, 
Finland 
N = 75 (14.4); 
MMSE = -  
Age = 83.0   
N = 446 (85.6); 
MMSE;  



















Hartikainen et al 
(64), 2005, 
Finland 
N = 77 (14.7); 
MMSE = -  
Age = -  
N = 446 (85.3); 
MMSE = - 



















Haasum et. al. 
(65), 2011, 
Sweden 
N = 119 (5.1); 
MMSE = 19.5r4.8; 
Age = 86 r6.5  
N = 2,199 (94.9);  
MMSE=28.4r2.0; 



















Bell et. al. (66), 
2011, Finland 
N = 28,089 (50.0); 
MMSE = -  
Age = 80  r 6.8  
N = 28,089 (50.0);  
MMSE= -  




















al. (67), 2014, 
Denmrk  
N = 19,470 (4.0); 
MMSE = - 
Age = - 
 
N = 463,402 (96.0); 
MMSE = - 




















Hamina et. al. 
(68), 2016, 
Finland   
N = 67,215 (50.0); 
MMSE = -  
Age = 80   
N = 67,215 (50.0);  
MMSE= -  



















Abbreviation: D: dementia; ND: no dementia; 
a Significant p-value for all people with dementia (nursing homes and community-dwelling)  
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The results from the literature search show that there are more home-dwelling PWD that used 
analgesics than people without dementia (Table 1.1). Studies from the early 2000s indicated 
that there were more people without dementia that used analgesics, compared to PWD. 
However, these studies were relatively small (Table 1.1). The newer, register-based studies 
have revealed that more people PWD used analgesics, especially for paracetamol. The 
prevalence is more spread for opioid use, were Jensen-Dahm et.al. reported more home-
dwelling PWD using opioids, while Bell et. al. and Hamina et. al. reporting slightly less PWD 
using opioids (66-68). Fewer people with dementia used NSAIDs according to the table. The 
finds from the literature were all from Nordic countries, which makes it more likely that 
analgesic prescribing in Norway are similar. However, we found no studies from Norway that 
looked at the analgesic prescribings home-dwelling PWD.  
 
Few studies have checked whether analgesic use differs according to cognitive function in 
PWD. One study from France did not find a significant difference in opioid use for people with 
low and high MMSE score (69). A small study from Northern Ireland also came to the same 
conclusion (36). No comparable studies have previously been conducted in the Norwegian 
population.  
 
1.7 Purpose of the study 
This thesis aims to investigate how analgesic use varies according to dementia severity and 
BPSD in home-dwelling PWD. No previous study has investigated the association between 
analgesic use and degree of cognitive impairment or BPSD symptoms in home-dwelling PWD 
in Norway.  
 
The main goal of this thesis is to describe and assess the prevalence and type of analgesic use 
in the study population of home-dwelling PWD. Furthermore, the thesis aims to determine if 
the prevalence and pattern of analgesic use in PWD differed according to their cognitive state. 
Secondary aims include the assessment of whether factors such as pain and BPSD affect the 









2.1.1 Study model 
This thesis is based on data from the LIVE@HOME.Path trial. LIVE@HOME.Path is an 
ongoing randomized controlled trial (RCT) aiming to implement and evaluate a 
multicomponent intervention for home-dwelling dyads of people with dementia (PWD) and 
their informal caregivers (caregiver). The intervention aims to enable and support PWD to 
remain living at home for longer, while maintaining safety and supporting independence for 
PWD through high-quality and cost-effective care. The study employs four main components 
facilitated by a coordinator that are listed in the acronym LIVE: Learning, Innovation, 
Volunteering, and Empowerment. The primary outcome of the study is resource utilization, 
described as both the time spent caring for the person as well as the care-related burden 
experienced by the informal caregiver. The secondary outcomes include assessments of change 
in quality of life, neuropsychiatric symptoms, level of independence in activities of daily living, 
presence of pain and clinically meaningful changes perceived by the caregivers (22).   
 
The study utilizes different study methods. The study has a mixed-methods design, including 
components of on both quantitative and qualitative study methods. The study has a stepped-
wedge design randomized controlled design, meaning that each participants starts receiving the 
intervention at sequential time periods determined through randomization. The participants 
waiting for the intervention acts as the control population (22). The LIVE@Home.Path 
intervention is a multicomponent intervention, meaning that it works by intervening in a 
complex system. The interventions focuses on disrupting prior ways of working while 
simultaneously introducing new ones (70).  
 
2.1.2 Participant recruitment 
The study population was selected out from different sources. Elderly people with dementia 
were referred to the study from policlinics located at two hospitals in Western Norway, NKS 
Olaviken Gerontopsychiatric Hospital and Haraldsplass Deaconess Hospital. Other 
participants where referred from the memory teams and municipal home nursing services in 
Bergen, Kristiansand and Bærum. Additionally, a small number of participants spontaneously 
volunteered to participants in the study after advertisement in general media such as 
newspapers, radio and TV in Bergen, Bærum and Kristiansand (22).  




Participants eligible for inclusion were PWD aged ≥ 65 years, home-dwelling, had a minimum 
of 1 hour regular weekly face-to-face contact with the informal caregiver, were diagnosed with 
dementia according to standard protocol in Norway (71), had a Mini-Mental State Examination 
(MMSE) score between 15-27 or a Functional Assessment Staging Test (FAST) score between 
4-7, and provided written informed consent (22). The trial included people with different forms 
of dementia and with other comorbid conditions. PWD were excluded if they participated in 
another ongoing intervention trial or expected survival time was less than 4 weeks (22). 
 
2.2 Data material used in this thesis 
This thesis utilizes data material from the baseline assessment (pre-intervention) for the 
LIVE@Home.Path trial. The data material will be used to conduct a cross-sectional, 
observational investigation of analgesic use in home-dwelling PWD receiving treatment as 
usual. We are using the participant’ medication history in combination with a selection of the 
assessment tools that were used to assess cognitive function and neuropsychiatric symptoms  in 
the baseline assessment. These procedures and tools will be described in detail in the following 
sections. Data gathered from the baseline assessment will be used to determine the prevalence, 
pattern and associated factors of analgesic use in this population, independently of the 
LIVE@Home.Path intervention (22).  
 
2.2.1 Data collection 
The baseline assessment was conducted from 24 May 2019 to 31 December 2019, where two 
study personnel went on a home visit to the person with dementia (PWD). The study personnel 
were either researchers connected to the Centre for Elderly and Nursing Home Medicines 
(SEFAS), or municipal health personnel.  Prior to the baseline assessment, the study personnel 
attended a one-day seminar to receive standardized training in data collection including 
interviews with the participants, scoring through relevant assessment tools, and the use of 
tablets in safe and direct data collection.. In addition, the study personnel had received a written 
study manual to guide them during the study visits in order to ensure standardized reporting 
(see Appendix 1). At the home visits, the study personnel gave verbal and written information 
to the PWD and caregivers about the trial and obtained a written informed consent before 
starting the baseline assessment. How the study obtained written consent is further described 
later in the thesis.  
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The baseline assessments were conducted as two interviews. One was with the PWD as an 
informant providing self-reported symptom assessments encouraged and supported by the 
caregiver, and one with the caregiver as self-rater but also an informant, providing observer-
rated symptom assessment (see Appendix 2 and 3). The interview with the PWD was conducted 
as the first part of the baseline assessment, initially with both study personnel, the PWD and 
their caregiver present in the room to ensure that the PWD would feel safe with the study 
personnel. The second part of the assessment of the PWD, including clinical assessments of 
pain, blood pressure, and body weight, was conducted with one study personnel and the PWD 
present in the room. During this part, the other study personnel would start interviewing the 
caregiver in a separate room (see Appendix 2 and 3).  
 
2.2.2 Medication list  
Most of the participants had a written list of prescribed medication from the municipal home 
healthcare services available in their homes, which was used to confirm the medication history. 
The study personnel could also obtain the medicine list for the PWD directly form the municipal 
home healthcare services with permission. The medication history included information about 
prescribed medicines, drug doses, administration form, dosage intervals, and if the medicines 
were used regularly or “as needed” (“pro re nata”; PRN) (See Appendix 2). The total number 
of prescribed drugs was counted, and divided into 3 categories. Polypharmacy was defined as 
concomitant use of ≥ 5 drugs (18), and the other two categories were set at 0 and 1 - 4 medicines.  
 
The analgesics were separated from the rest of the medication list for the analyses. The 
analgesics included in the analysis were approved and marketed as pharmaceuticals in Norway 
by the Norwegian Medicines Agency (NoMA) with analgesia as primary indication. The list of 
analgesics was gathered from Felleskatalogen (www.felleskatalogen.no), which contains an 
overview of marketed pharmaceuticals in Norway and their product monographs. We defined 
as analgesics all substances that were classified within the Anatomical Therapeutic Chemical 
(ATC) classification system as ATC groups N02A (opioids), N02B (other analgesics and 
antipyretics), N02C (antimigraine preparations), M01A (anti-inflammatory and anti-rheumatic 
preparations, non-steroid) and M02AA (topical products for musculoskeletal pain). Medicines 
that may be used as adjuvant analgesics meaning that they have other main indications for use 
besides pain, such as tricyclic antidepressants (TCA) and anti-epileptic medicines, were 
excluded because information about indication for use was not registered in the data material.  
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Analgesic prescriptions were further described in detail by generating new variables. First, all 
analgesic prescriptions were classified according to use pattern in the two main categories of 
regularly scheduled and PRN use. In the following, unless otherwise specified, analgesic use 
is defined as having one or more prescriptions of regularly scheduled analgesics (excluding 
PRN prescriptions because frequency of use is unknown). Furthermore, the analgesics clases 
were further classifying into the following four main categories, which is listed in Table 2.1. 
Paracetamol was counted as a separate variable since it is the single most commonly used 
analgesics among elderly and people with dementia (72).   
 
Table 2.1 List of analgesics included in the study  
Analgesic class   ATC code  
Opioids N02A 
NSAIDs M02A, M02B 
Paracetamol  N02BE01 
Others  N02B [except N02BE01], N02C 
 
The individual dosages (ID) for each analgesics (regular use only) were calculated for 
analyses, by dividing ID with defined daily dosage (DDD) (73).  
 
2.2.3 Assessment scales  
The Mini-Mental State Examination (MMSE) was used to assess cognitive function (74). 
The MMSE scale is not intended for use as a diagnostic tool for dementia or cognitive 
impairment, but is validated as a screening tool for cognitive decline in clinical and research 
settings (75). The test is administered by health personnel and consists of twenty questions and 
tasks designed to assess domains of cognitive functions. It is a score-based system that ranges 
from 0-30, where the maximum score indicates no cognitive decline (74). The 
LIVE@Home.Path study used MMSE-NR3 (Appendix 4), which is a revised version adapted 
for the Norwegian population (22, 71).  
 
In this paper, the participants have been classified in the three main categories mild, moderate 
and severe cognitive impairment based on their MMSE score. Since the test is not used as a 
diagnostic tool, the test score has been used as a guideline to group the study population based 
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on the severity of the dementia. The cut off value was set at ≥ 21 for mild dementia and ≤ 20 
for moderate dementia (76).  
 
The Neuropsychiatric Inventory (NPI-12) is a validated clinical instrument used to assess 
neuropsychiatric symptoms or behavioral and psychological symptoms in dementia (BPSD) 
(77). The test is a proxy or observer rated test, where the informant (caregiver) reports whether 
the PWD has experienced neuropsychiatric symptoms in the last month (77, 78). The NPI-12 
test is validated in other countries, but not in Norway. The validated test in Norway, 
Neuropsychiatric Inventory, Nursing Home version (NPI-NH), is similar to the NPI-12, 
however the questions are rephrased to reflect the professional relationship between PWD and 
their professional caregiver (79). In the LIVE@Home.Path trial, the informal caregivers have 
acted as the proxy raters for the PWD (22). NPI-12 assesses BPSD within 12 domains: delusion, 
hallucination, agitation/aggression, depression/dysphoria, anxiety, irritability/lability, apathy, 
disinhibition, euphoria/elation, aberrant motor activity, nighttime behavioral disturbance and 
appetite disturbance. Each symptom is scored based on the frequency and severity of the 
reported signs and behaviors (77) (See appendix 3 for the point system).  
 
To get the NPI domain score, the frequency score is multiplied by the severity score, yielding 
a domain score that ranges from 0: not present; to 12: most frequent and severe (77). The NPI 
total score is the sum of all the NPI domain scores, yielding a total score that ranges from 0-
144 points (80).  
 
The NPI domain and total scores were dichotomized to describe the presence of clinically 
significant symptom burden (yes/no) for some of the statistical analyses. The cut-off value for 
NPI-12 total was set at ≥ 12, whereas the domain scores were defined as clinically relevant at 
≥ 4 level (81).  
 
The Cornell Scale for Depression in Dementia (CSDD) is a validated for the assessment of 
depressive symptoms in people with dementia (82). The test is-proxy rated, and the informant 
(here; caregiver), reports the presence and severity symptoms during the preceding week. The 
instrument consists of 19 items that covers symptoms of depression grouped into  mood related 
signs, behavioral disturbance, physical signs, cyclic function and disturbance of thoughts. Each 
item is rated from 0-2 (0 for absent, 1 for mild/intermittent, 2 for severe). The total score is the 
sum of all the item score, ranging from 0-38 points. The CSDD score was also dichotomized 
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for some of the analyses, using a cut-off value for CSDD total score of ≥ 8 for clinically relevant 
depressive symptoms (83). The cut off was set at 8 instead of 6 in order to avoid false positive 
test (83). The assessment method has been validated and is reliable for clinical depressive 
symptoms (84, 85). 
 
The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item, validated questionnaire that 
is used to assess the severity of agitation in people with dementia. The questionnaire is proxy- 
rated and the informant (here: caregiver) reports how frequently they have observed 29 different 
agitated behaviors during the last two weeks. The symptoms can be divided into four main 
categories: aggressive behavior, physical non-aggressive behavior, verbally agitated behavior, 
and hiding and hoarding (86). The frequency of each behavior is rated from 1: never, to 7: 
several times per hour (Appendix 3). The item scores are added to yield the total CMAI score, 
which ranges from 29-203 points (22, 87).  The CMAI score was dichotomized for some of the 
analysises, using ≥ 44 as the cut-off for clinically significant agitation (88).  
 
The variables NPI-NH total score, CSDD score and CMAI score are cumulative scores. The 
scores were considered valid if answers were provided for at least 80% of the NPI domains, 
CSDD domains and CMAI items respectively.  
 
The Mobilization-Observation-Behavior-Intensity Dementia-2 Pain Scale (MOBID-2) is a 
tool to detect pain among people with dementia. The assessment and scoring can be done in 5 
minutes total. The test is divided into two parts. The first part of the assessment (MOBID-2 part 
1) is based on observations during standardized movements in order to see if the person with 
dementia is displaying signs of pain when they move. The test is conducted in the morning 
when the patient is going through morning routine. The health personnel leads the PWD to do 
five different movements: 1. opening their hands; 2. stretching their arms over their head; 3. 
bending and stretching ankles, knees and hip joint; 4. turn around in bed to both sides; 5. sit up 
on the edge of the bed (Appendix 2)(89). The LIVE@Home.Path trial modified the procedures 
for movements  4 and 5 because MOBID-2 assessment were carried out when the person was 
out of bed, usually in the living room (Appendix 1). The PWD could instead lay down on the 
sofa for point 4, and rise up to a sitting position for point 5 (Appendix 1).  
 
After each movement, the study personnel observes if the PWD displayed pain through 
vocalization, facial expressions or acts of defense. The study personnel would interpret the pain 
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intensity in each location using a numeric rating scale (NRS) from 0 (no pain) to 10 (worst 
possible pain) (89).  
 
For the second part of the assessment (MOBID-2 part 2) pain, the test focuses on pain in the 
internal organs, head and skin. The health personnel asks the PWD if they have had pain today 
and the past week in the following areas: 6. head, mouth, neck; 7. breast, lungs, heart; 8. 
stomach – upper part; 9. pelvis, stomach – lower part; 10. skin, infections, wounds (Appendix 
2)(89); The study personnel can also show a drawing of the body to the PWD in order for the 
person to show where it hurts. Based on the observation of vocal, facial expressions and acts of 
defense, the study personnel interpreted the behavior and used the same NRS tool to rate the 
pain from 0 (no pain) to 10 (worst possible pain) for each of the locations (89, 90). At the end 
of the assessment, the study personnel used all available information to estimate overall pain 
intensity experience by PWD, to yield the MOBID-2 total score (NRS range 0-10) (89, 90).  
 
MOBID-2 total was transformed to describe three levels of pain for some of the analyses. The 
cut off values for MOBID-2 total were set at 0-2 for no to mild pain, 3-6 for moderate pain and 
7-10 for severe pain (89). Information about pain reactions from different body locations 
collected during the MOBID-2 assessment (part 1 and 2) was also used to generate a new 
variable describing the number of painful locations; for this variable, locations were counted as 
painful if the corresponding NRS subscale had a score of ≥3 (91, 92).  
 
The European Quality of Life – 5 Dimensions – 5 Levels (EQ-5D-5L) is an assessment tool 
that evaluates self-reported health-related quality of life. This thesis uses the result from one of 
the five items in the test regarding pain and discomfort. PWD reported if they experienced pain 
or discomfort today though a five-point verbal scale ranging from no discomfort to very strong 
pain and discomfort. The result was afterwards converted to a numeric scale of 0-5, where five 
means the person experienced severe pain (22, 93). The EW-5D-5L item score was 
dichotomized for some of the analyses.   
 
2.3 Statistical analysis 
There were several statistical methods used in this thesis. The Person  F2 – test was used to 
check for between-group differences within demographic variables and the use of analgesics. 
The demographic variables tested were for gender, age, MMSE score, number of medications, 
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if medication review was conducted during the last six months with general practitioner (GP) 
and living situation (living with).  
After dichotomization the participants according to score, between-group differences in 
analgesic use were also tested for the assessment scales MMSE, MOBID-2, EQ-5D-5L 
(pain/discomfort item), NPI-12, CSDD and CMAI using Person F2 – test. The demographic 
variables and the grouped assessment-based variables were chosen as the independent variables 
(exposures), while the dependent variable (outcome) was analgesic use . The outcomes were 
reported in frequency tables with p-values (p) (94).  
 
Associations between analgesic use and pain (MOBID-2, EQ-5D-5L) cognitive status 
(MMSE), and BPSD (NPI-NH total score and single domains; CSDD; CMAI) were further 
investigated using simple and multivariable logistic regression and binominal regression as 
appropriate. The assessment variable was chosen as the independent variable for crude 
regression, with analgesic use as dependent variable. Adjusted regressions analyses used in 
addition age, gender and MMSE score as independent covariates. The outcome variable was in 
binary form (yes/no), while the independent assessment variables and covariables were in 
continuous form. The results were presented as odds ratio (OR) and relative risk (RR) with p-
values for association.   
 
Linear regression was also used in order to find association between analgesic use and pain, 
cognitive status and BPSD. The first regression was with dementia symptoms (MMSE; NPI-
NH single domains; CSDD; CMAI) as independent variable (exposure) and MOBID-2 as 
dependent variable (outcome). The second regression had the same independent variables with 
dementia symptoms, while the dependent variable was ID. The adjusted regressions included 
the independent variables age, gender and MMSE score as covariates. Both the outcome and 
dependent variable was continuous for these regressions, except for age which was continous. 
The results were reported with coefficients, which describes the increase or decrease DDD 
scores when dementia symptoms increases.   
 
All the statistical analysis where conducted using the software program Stata/SE version 16 for 
Windows. The significance level for all analyses was set at 0.05, which meant that there was 
no significant difference if the p-value was over 0.05. If the p-value for one of the analyses was 
below the significance level, then there was with over 95% certainty a significant difference 
(94).  
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2.4 Contribution and ethics  
2.4.1 Contribution 
I started the master thesis in September 2020, which means I did not participate in the baseline 
assessment. Since joining the research group, I have participated in the 18-month data collection 
as a study personnel preforming around 40 interviews in Bergen. As a consequence of the 
COVID-19 pandemic, I had to do the interviews by telephone. This caused the data collection 
to be limited, where only the caregiver were interviewed and some assessment scales were not 
performed. In addition, I coded the medication lists from 12 month data collection by ATC. 
 
2.4.2 Ethical approval  
In May 2019, The LIVE@Home.Path trial was approved by the Regional Committee for 
Medical and Health Research Ethics (REC) in North Norway (2019/385) and West Norway 
(2017/1519). The trial was registered at the ClinicalTrials.gov (NCT04043364). In addition, he 
LIVE@Home.Path trial developed a Data Protection Impact Assessment (DPIA) (ePhorte UiB: 
2019/5569) with the University of Bergen (UiB). DPIA is a formal process to minimize the 
data protection risks for a project (22). This thesis was approved by REC in North Norway 
(2021/10861) in March 2021. Also, I was approved  to access to the designated SAFE server at 
UiB, which provides LIVE@Home.Path with secure transfer and storage of sensitive data. 
Using this solution, I could work with data management and analysis of pseudoanonymous data 
material while maintaining a high level of security (22).  
 
Both the PWD and their caregivers were given information verbally and in written form. The 
caregiver, and the PWD if capable of providing consent, had to provide a written informed 
consent before participating in the trial. In case it was not possible, the next of kin or a legal 
advocate could provide a written informed consent. They would had to determine if the PWD 
would have agreed to participate in a trial before they developed dementia (22).  
 
3. Results  
Figure 3.1 show a flow chart of participants that were included in the LIVE@Home.Path trial, 
which is described in the blue boxes. There were 438 participants that were recruited to the 
LIVE@Home.Path. By the end of the recruitment period 158 participants were excluded, 
ending up with N = 280 participants. For the different assessment scores, there are some missing 
data in the data material.  
























Abbreviation: n = number of participants  
Figure 3.1 Flow chart of the participants in the LIVE@Home.Path trial (22, 95) 
 
 
3.1 Characteristics of study population   
A total of 280 home-dwelling, people with dementia (PWD) participated in the 
LIVE@Home.Path trial. The participants lived in three Norwegian cities, 124 in Bergen, 94 in 
Kristiansand and 62 in Bærum. The characteristics of the study population are listed in Table 
3.1. N, represents the total population for each variables, while n represents subgroups for each 








- Lack of consent (n=59) 

















Missing / excluded data in data set  
- MMSE (Missing = 16)  
- NPI-12 (Missing = 12) 
- CSDD (Missing = 15; excluded = 3 because of incomplete answers) 
- CMAI (Missing = 12) 
- MOBID–2 (Missing = 9) 
- EQ-5D-5L (Missing = 9) 
January 2020 
May 2019 
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Table 3.1. The demographic of the study population, N=280a  









Age in years (N=276) 
- 65-74 
- 75-84 





MMSE total (N=264) 
- ≤ 20 




Number of medications (N=280) 
- 0 medicines 
- 1≤ 4 medicines  











Living with (N=264) 
- Alone (N=127) 
- Spouse/partner (N=132) 





The percent is the share of people within each subgroup of characteristics  
a Some of the numbers may not add up because of missing values   
cCnversation with general practitioner (GP) within the last 6 months regarding medications 
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Figure 3.2 Distribution of age and sex according to MMSE score (put inn ny graf) 
 
The study population consistsed of 174 (62.5%) women and 104 (37.4%) men (Table 3.1). The 
mean age for PWD was 82.1 years (standard deviation 6.7), the youngest was being 66 years 
old and the oldest person being 97 years. The age distribution was concentrated on patients 
aged 75 years and over. There were 122 people (44.2%) aged 75 years to 84 years who 
participated, while there where 104 people (37.7%) aged 85 years and older. The youngest 
group aged 65 to 74 consisted of 50 people (18.1%). Regarding living situation, 127 people 
(48.1%) lived alone while 132 people (50.0%) lived with their spouse or partner and 5 people 
(1.9%) had other relationship to their cohabitants 
 
The MMSE score indicate that there was an even distribution of people with mild and moderate 
cognitive impairment. The average MMSE score was 20.7 (standard deviation 3.8), which is at 
the threshold between mild and moderate cognitive impairment. 139 people (52.7%) had mild 
cognitive impairment (MMSE score between ≥ 21), while 123 people (46.6%) had moderate 
cognitive impairment (MMSE score ≤ 20). The range was from 7-29, meaning some of the 
participants was under the inclusion mark (MMSE ≥15, 10 PWD) and over (MMSE ≥ 27, 7 
PWD). However, they were within the FAST requirement. The distribution between the 
different MMSE group adjusted for age and sex is illustrated in Figure 3.2.  
 
The general use of medicines was high, with only 22 people (7.9%) of the study population 
reporting no use of medicines. There were 141 people who used 5 or more medicines, which is 
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over 50% of the study population, while 117 people (41.8%) used 1 to 4 medications. In 
addition, 143 people (51.8%) reported that they had not discussed medication use with their 
general practitioner during the last six months.   
 
3.2 Characteristics of analgesics  
Table 3.2 describe how many people used opioids, NSAIDs, paracetamol and others analgesics. 
In addition, it describes how many people used analgesics regularly and PRN within each class. 
 
Table 3.2 Types of analgesic prescribing and frequency for regular/on-demand use  
 Regular use (%) PRN use (%) Total use (%) 
Analgesic use total 
- 1 prescription  
- 2 prescriptions  














- 1 prescription 
- 2 prescriptions  





















Paracetamol used  
- 1 prescription 










Other analgesics used  







Total prescriptions include regular and PRN use for each class  
Percent is share of the study population. 

















Figure 3.3 Regular use of analgesics in the study population 
 
A total of 90 participants were prescribed analgesics for regularly scheduled and/or PRN use. 
That makes up 32.1% of the study group. 76 (27.1%) of the study population one analgesic 
prescribing, while 14 (5.0%) of the study group had two or more prescriptions for regular or 
PRN analgesics.  
 
Furthermore, 55 (19.6%) people reported using analgesics regularly, while 39 (13.9%) people 
used analgesics on-demand. Figure 3.3 illustrate the regular use of analgesics among the study 
population. Paracetamol was the most widely used analgesics, while opioids and NSAIDs were 
infrequently used.  
 
Table 3.3 further explains how many people used prescriptions within the different classes. 16 
(5.7%) people were prescribed opioids, 13 of them on a regular basis. And there where 2 (0.7%) 
people who used ≥ 2 opioids regularly and/or when needed. For NSAIDs, 15 (5.4%) people 
used one prescription. Out of the 15 people, 9 of them used NSAIDs on a regular basis. For 
paracetamol, 69 (24.6%) people used one or more prescription. 41 (14.6%) people used 
paracetamol regularly and 1 person used paracetamol regularly and PRN. Other analgesics used 
was anti-migraine analgesics, which 3 (1.1%) people used PRN.   
Amina Abdirahman Sheikh                                                                                  
 35 
Table 3.3 Most common analgesics used among participants   
Regularly used analgesic PRN used analgesic 
Medication n ATC  Medication n ATC 
Paracetamol 41 N02BE01 Paracetamol  29 N02BE01 
Buprenorphine 
(TDP) 
6 N02AE01 Codeine + 
paracetamol 
5 N02AJ06 
Glucosamine 5 M01AX05 Diclofenac (gel) 3 M02AA15 
Fentanyl (TDP) 3 N02AB03 Sumatriptan 2 N02CC01 
Codeine +  
paracetamol 
2 N02AJ06    
Tramadol 2 N02AX02    
Abbreiation: TDP, transdermal patches  
 
Table 3.3 understates the finds from Table 3.2 and Figure 3.3. Paracetamol was the most used 
prescription among the study population, both for regular and on-demand use. Few people used 
opioids, however the most common prescriptions wre transdermal patches with strong opioids 
such as buprenorphine (6 people) and fentanyl (3 people). Other analgesics used were 
combinations prescriptions with paracetamol and codeine, mostly used PRN. 9 people (3.2%) 
used one or more strong analgesics, all prescriptions regularly. Furthermore, 9 (3.2%) people 
used one weak analgesics, were 4 of them took them regularly. In terms of NSAIDs, 
glucosamine was the most common analgesics with 5 people using them regularly. The other 
analgesics described in Table 3.3 was used rarely.  
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Table 3.4 further describes what type of analgesics had been prescribed to people according to their cognitive function (MMSE score), both for 
regular and PRN use.  
 









Abbreviation: MMSE, Mini Mental State Evaluation; NSAIDs, Non-Steroid Anti-inflammatory Drugs 
a Numbers do not add up to 280 due to missing values  
b No participants used other analgesics regularly, 3 people used on-demand 
* All p-value > 0.05, Person chi-square test  
 
4 (3.2%) of the people using opioids regularly had moderate cognitive impairment (MMSE score ≤20), while 9 (6.5%) participants had mild 
cognitive impairment (MMSE score ≥ 21). The same pattern follows for regular use of NSAIDs, where participants with a higher total MMSE 
score use more NSAIDs. 20 (16.0%) of the people using paracetamol regularly had a moderate cognitive impairment, while the remaining 19 
(13.7%) participants had a mild cognitive dementia. A Chi square test was performed to see if there was a group difference between participants 
with mild and moderate cognitive impairment. The p-values were not significant for any analgesic class, meaning there were no significant 
difference the two groups and the use of regular analgesics (p-value > 0.05).    




N (%)  
264 (100%) 
Opioids   
n (%)  
13 (4.9%) 
NSAIDs  
n (%)  
9 (3.4%) 
Paracetamol 
n (%)  
39 (14.8%) 
Opioids  
n (%)  
5 (1.9%) 
NSAIDs  
n (%)  
6 (2.3%) 
Paracetamol  
n (%)  
29 (11.0%) 
Others b 
n (%)  
3 (1.1%) 
≤20  125 (47.3) 4 (3.2) 2 (1.6) 20 (16.0) 0 (0.0) 2 (0.8) 11 (8.8) 1 (0.8) 
≥ 21   139 (52.7) 9 (6.5) 7 (5.0) 19 (13.7) 5 (3.6) 4 (2.9) 18 (13.0) 2 (1.4) 
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For PRN use, all 5 participants who used opioids had a MMSE-score ≥ 21. 2 (0.8%) of the 
participants who used NSAIDs PRN had a MMSE score ≤ 20 and 4 (2.9%) participants had a 
MMSE score above 20. For paracetamol, 11 (8.8%) participants had moderate cognitive 
impairment, while 18 (13.0%) had mild. In addition, three people used other analgesics PRN 
where the distribution was mostly even. After performing a Chi square test, the p-values were 
again not significant for any analgesic classes (p-value > 0.05). It meant that there was not 
found a between-group difference in the use of PRN analgesics within MMSE score.   
 
3.3 Analgesic prescribing for PWD according to demographic characteristics 
Table 3.5 used Person 𝜒2 – test in order to find out if there was a significant difference between 
the subgroups in each characteristics and regular use of analgesic regularly. 
 
Table 3.5. Analgesic prescribing for PWD according to demographic characteristics 
Characteristics Total  
N (%)  
280 (100) 
Uses  analgesics 
reg N (%)  












Age in years (N=276) 
- 65-74 
- 75-84 










MMSE total (N=264) 
- 0-10 
- 11-20 










Number of medications (N=280) 
- 0 medicines 
- 1≤ 4 medicines  
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- No 143 (51.8) 32 (22.4) 
Living with (N=264) 
- Alone  
- Spouse/partner  










The percent is the share of people within each subgroup of characteristics  
a Some of the numbers may not add up because of missing values   
bConversation with general practitioner (GP) within the last 6 months regarding medications 
*P-value tested through Person chi- test  
 
There was a significant gender difference and the use of analgesics. More women used 
analgesics than men, with 41 (23.6%) women reporting prescriptions for one or more daily 
scheduled analgesics. In comparison, 14 (13.5%) men used analgesics regularly (p = 0.041). 
Age was also significantly related to the use of analgesics. The older age groups used more 
analgesics compared to the youngest age group. Around 22% to 24% of people in the older age 
groups used analgesics, while 6.0% of the 65-74 age group used analgesics regularly (p-value 
= 0.048). And there was a significant difference between analgesic use among participants 
classified according to total number of regularly scheduled prescriptions or polypharmacy. 44 
(31.2%) of the people with ≥ 5 medicines had also used analgesics regularly, while 11 (9.4%) 
of the people with 1 ≤ 4 medicines used analgesics regularly.  
 
The two last variables, medication review with GP and living situation, yielded non-significant 
association with analgesic use. Out of the 55 people who used analgesics regularly, 32 had not 
discussed their medication or had a medication review with their general practitioner in the last 
six months. That is almost 60% of the people using regular analgesics. 23 (17.3%) of the people 
who had discussed with GP about their medication used analgesics regularly. For living 
situation, 31 individuals or 24.4% of the people who lived at alone used analgesics regularly. 
In comparison, 20 people (15.2%) living with a partner used analgesics regularly.  
 
There were other characteristics that did not have a significant association to analgesic use. The 
MMSE score was tested to see if there was a difference between people with different cognitive 
status. 29 (20.9%) of the people with mild dementia and 24 (19.5%) of the people with moderate 
dementia used analgesics regularly. 7 of the people with mild dementia used two analgesics 
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regularly, compared to 2 people with moderate dementia. However, there was no significant 
difference connected to the severity of dementia and the use of analgesics (p = 0.573).  
 
3.4 Analgesic prescribing for PWD according to pain   
Table 3.6 describe how many participants were reported to have pain, through self-report (EQ-
5D-5L; item pain/discomfort) and through proxy rating from the study personnel who assessed 
the PWD (MOBID-2 score total score [intensity]; MOBID2-locations). The table also describes 
if there was between-group differences within the pain variables and the use of analgesics.  
 
Table 3.6 Reported pain in the study population N = 280a  
Abbreviation: MOBID-2, Mobilization – Observation- Behaviour – Intensity – Dementia Pain scale 2 
a Numbers may deviate from 280 because of missing values  
b P-value by Person F2 – test. 
 Number of 
participants 
No analgesic 
use (% of group) 
Regularly  analgesic 
use (% of group) 
pb 
Pain today (EQ-5D-5L) (N=271) 
- No to little pain 
- Moderate pain 














MOBID-2 total score (N=271) 
- No to mild (0-2) 
- Moderate (3-6) 














MOBID-2 locations with MOBID-2  
score ≥ 3 (N=269)c  
- 0 location with pain 
- 1 location with pain 
- 2 locations with pain 
- 3 locations with pain 
- 4 locations with pain 
- 5 locations with pain 
- 6 locations with pain 
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c 275 participants were registered with ≥ 1 answer, 6 people were excl. since under < 80% of the questions were 
registered.  
 
Self-reported level of pain according to EQ-5D was classified as moderate in 38 participants, 
while 15 people had self-reported strong to very strong pain. That is in total 53 participants or 
19.6% of the study population. The remaining 218 participants (80.4%) had reported no to little 
pain.  
 
Meanwhile, health personnel reported that 40 (14.8%) participants had pain of moderate to 
severe intensity (MOBID-2 total score ≥ 3). The MOBID-2 location score shows that 86 people 
(32.0%) had at least one location where they had clinically relevant pain (MOBID-2 score ≥ 
3). 183 people (68.0%) had not reacted with clinically relevant pain to any location. More 
people were registered to have significantly painful locations (86 people) compared to people 
with a MOBID-2 total score ≥  3 (40 people).  
 
The Chi square test showed when it came to analgesic use, there was a group difference between 
participants who self-reported significant pain (EQ-5D ≥ moderate) and the group who had not 
self-reported significant pain (P-value < 0.001). 18 (47.4%) in the group self-reporting 
moderate pain used analgesics regularly, while 8 (53.3%) in the group self-reporting strong to 
very strong pain used analgesics regularly. Correspondingly, 29 (13.3%) in the group who self-
reported no to little pain used analgesics regularly.  
 
There was also a significant between-group difference within the MOBID-2 total score variable. 
17 (42.5%) in the group who were reported to have moderate to severe pain (MOBID-2 total 
score ≥ 3) used analgesics regularly. In comparison, 38 (16.5%) in the group who were reported 
to have no to little pain (MOBID-2 total score ≤ 2) used analgesics regularly. MOBID-2 location 
follows the same patterns as the other pain-related variables, with a significantly higher number 
of analgesic users among those with a higher number of painful locations (p = < 0.001). The 
share of people who used analgesics regularly increased from 13.1% for no painful locations, 
to over 60% for people who had 7 painful locations.   
 
Further description of the association between painful conditions and regular analgesic use is 
in listed in table 3.7.  
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Table 3.7 Association between analgesic use and pain (MOBID-2 scores; MOBID-2 location), 
n = 55 of 280   
  Crude  Adjustedb 
Independent RR OR (95% CI) p-value 
(0.05)  






1.490 r 0.133 
(1.251 – 1.775) 
<0.001 1.218 r 
0.051 
1.499 r 0.138 
(1.252 – 1.796) 
<0.001 
MOBID-2 
pain ≥ 3 
2.584 r 
0.610 
3.754 r 1.373 
(1.833 – 7.689) 
<0.001 2.651 r 
0.615 
3.821 r 1.429 






1.683 r 0.185 
(1.357 – 2.089) 
<0.001 - b 1.665 r 0.185 
(1.340 – 2.071) 
<0.001 
Abbreviation: RR, Relative Risk; OR, Odds Ratio; MOBID-2, Mobilization-Observation-Behaviour-Intensity-
Dementia scale 2 
a Adjusted for age, sex and MMSE score (dichotomized in the categories as mild ≥ 21 and as moderate to severe 
≤ 20 cognitive impairment) 
c No results since the regression could not be completed with age, sex and MMSE score as independent
The table show that there was a significant association between regular use of analgesics and 
increasing MOBID-2 score (crude OR 1.49, 95% CI 1.25-1.78). It means that for one unit 
increase in MOBID-2 total score, the odds of using analgesics regularly increases with 1.49 
times (49%). The CI show that the difference in odds span from 25% to 78%. The OR was a 
little higher when adjusted for age, sex and MMSE score (adjusted OR 1.537, 95% CI  1.269 – 
1.861). The risk ratio between analgesic use and MOBID-2 score was 1.23 for crude and 1.22 
for adjusted, which means there was a 22-23% increased risk that a person uses analgesics when 
MOBID-2 score increases with 1 point. All the values were significant (p-value < 0.001).  
 
There was also a significant association between analgesic use and MOBID-2 location score. 
The crude OR was 1.683 (standard deviation 0.185), which means that if a participant had one 
more clinically relevant painful location (MOBID-2 score ≥ 3), the odds for using analgesics 
would increase with 1.683 times (68%). The CI for the difference in odds span from 36% to 
109%. The adjusted OR was also higher than crude OR (1.731, 95% CI 1.371 – 2.186).  
 
 
3.5 Analgesic prescribing according to dementia symptoms  
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Before checking for an association between analgesic prescribing and dementia symptoms, we 
checked if participants with dementia symptoms were reported to have more pain. Table 3.8 
describes if there is an association between pain (MOBID-2 total score) and having dementia-
related symptoms.   
 
Table 3.8 Association between MOBID-2 score and dementia symptoms   
Abbreviation: CI, Confidence Intervall; MOBID-2, Mobilization-Observation-Behaviour-Intensity-Dementia 
scale 2; NPI, Neuropsychiatric Inventory; CSDD, Cornell Scale for Depression; CMAI, Cohen Mansfield 
Agitation Inventory 
a Adjusted for age, sex and MMSE score  
 
The table showed that MOBID-2 scores were not significantly associated with any of the 
independent variables which described cognitive status (MMSE) and BPSD (NPI-12 domains, 
CSDD, CMAI) (p > 0.05). The estimated coefficients described how much MOBID-2 score 
increased or decreased when the independent variables increased with one unit. For instance, 
NPI agitation had a coefficient of -0.068 (standard deviation 0.044). It meant that MOBID-2 
score decreased with 0.068 points when NPI agitation score increased by one point. The 95% 
 Crude Adjusteda 
Independent 
variable  
Coefficient 95% CI p-value 
(0.05) 
Coefficient 95% CI p-value 
(0.05) 
MMSE 0.021 r 
0.025 
-0.029 - 0.071 0.406 0.022 r 
0.025 





-0.154 - 0.018 0.119 -0.059 r 
0.045 
-0.147 - 0.029 0.187 
NPI anxiety  0.022 r 
0.034 
-0.044 - 0.089 0.512 0.032 r 
0.033 





-0.018 - 0.118 0.151 0.059 r 
0.034 







-0.156 – 0.057 0.363 -0.046 r 
0.054 
-0.152 – 0.060 0.393 
CSDD 0.022 r 
0.020 
-0.019 - 0.062 0.292 0.031 r 
0.020 
-0.009 - 0.071 0.124 
CMAI -0.005 r 
0.012 
-0.028 - 0.018 0.679 0.001r 
0.012 
-0.022 - 0.024 0.917 
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CI was between -0.154 – 0.018.  It meant that the difference in MOBID-2 score laid between 
the two numbers,  including 0 point difference when NPI-agitation increases by one point. The 
CI indicated that the results were not significant, and the p-value was above significance level 
(p > 0.05). The same pattern follows for all the independent variables, both crude and adjusted.  
 
Table 3.9 describes how many of the participants had clinically relevant BPSD scores (NPI-12 
score ≥ 12, NPI-domain score ≥ 4, CSDD score ≥ 8 and CMAI score ≥ 15) and the average 
score. Furthermore, the table describes how many people with significant BPSD symptoms 
used analgesics and if there were significant group differences within each BPSD variable. 
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Table 3.9: Use of analgesics and Behavioural and Psychological Symptoms in Dementia (BPSD), N = 280a  
Independent variables Mean r SD People without 
symptoms 
 
Regularly  analgesic 
use without symptoms 





use with symptoms 
n (% of group) 
p-value 
(0.05) 
NPI-12 total score (N=268) 16.7 r 15.7 116 23 (19.8) 152  30 (19.7) 0.985 
- NPI delusion (N=267) 1.38 r 2.48 223 47 (21.1) 44 6 (13.6) 0.258 
- NPI hallucination (N=265) 0.72 r 2.15 246 48 (19.5) 19 4 (21.1) 0.871 
- NPI agitation (N=267) 0.99 r 2.27 243 47 (19.3) 24 6 (25.0) 0.507 
- NPI depression (N=267) 1.84 r 2.88 209 39 (18.7) 58 14 (24.1) 0.355 
- NPI anxiety (N=264) 1.60 r 2.96 211 38 (18.0) 53 15 (28.3) 0.094 
- NPI euphoria (N=263) 0.21 r 0.97 257 51 (19.8) 6 1 (16.7) 0.847 
- NPI apathy (N=265) 2.51 r 3.74 188 36 (19.2) 77 17 (22.1) 0.588 
- NPI disinhibition (N=265) 0.75 r 1.84 243 42 (17.3) 22 9 (40.9) 0.007 
- NPI irritability (N=268) 1.62 r 2.78 212 45 (21.2) 56 8 (14.3) 0.246 
- NPI motor dist (N=267) 1.19 r 2.86 230 47 (20.4) 37 6 (16.2) 0.550 
- NPI sleep disturb (N=264) 1.71 r 3.17 206 41 (19.9) 58 10 (17.2) 0.650 
- NPI appetite (N=267) 2.28 r 3.67 196 34 (17.4) 71 19 (26.8) 0.088 
CSDD (N=262) 5.9 r 5.0 177 33 (18.6) 85 19 (22.4) 0.481 
CMAI score (N=268) 38.2 r 8.5 207 38 (18.4) 61 15 (24.6) 0.283 
Abbreviaton: NPI-NH, Neuropsychiatric Inventory for Nursing homes; CSDD, Cornell Scale for Depression in Dementia; CMAI, Cohen-Mansfield agitation inventory. 
a   Numbers deviates from 280 participant due to missing values. 12 people did not answer any questions for NPI-NH total, 15 people for CSDD and  12 people for CMAI  
CSDD: 3 answers form participants were excluded since they answered less than 80% of the CSDD domains. 
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For NPI-12 total score, the mean value was 16.7 r (standard deviation r 15.7). 152 (56.7%)  
people in the study population had clinically relevant neuropsychiatric symptoms (NPI-12 total 
score ≥ 12). For the NPI-domains, 24 participants were reported to have clinically relevant 
agitation, 58 people had clinically relevant depressive symptoms and 53 participants had 
clinically relevant symptoms of anxiety (NPI domain score ≥ 4). Other prevalent NPI domain 
symptoms are apathy (77 people), irritability (56 people), sleep disturbance (58 people) and 
appetite disturbance (71 people).  
 
The CSDD mean score was 5.9 (standard deviation r 5.0). There were 85 (32.4%) people in the 
study population who had clinically relevant depressive symptoms (CSDD ≥ 8). More 
participants were considered to have clinically relevant depressive symptoms according to the 
CSDD score, compared to NPI-depression score (58 people).  
 
The mean score for CMAI was 38.2 (standard deviation r 8.5). 61 (22.8%) of the participants 
were reported to have clinically signs for agitation (CMAI score ≥ 44). There was a difference 
in the number of participants who had clinically relevant signs for agitation dependent on which 
assessment scale was used. Only 24 participants were considered to have to have clinically 
relevant agitation through the NPI agitation score, while the CMAI assessment yielded over 
double the amount of people.  
 
For total NPI-12 total score, 30 (19.7%) people with clinically relevant neuropsychiatric 
symptoms used analgesics regularly. In comparison, 23 (19.8%) of people without relevant 
NPI-12 score used analgesics. For the NPI-domains, the use of analgesics ranged from 13.6% 
for people with signs of clinically relevant delusion to 40.9% for people with disinhibition. 
Participants without clinically relevant NPI domain scores would often have similar prevalence 
for analgesic use.  
 
The Chi-square test showed that when it came to analgesic use, there was not a significant group 
difference within the NPI-12 variable (p > 0.05). The Chi-square test gave only one significant 
result, which was for NPI disinhibition (p = 0.007). It means that in regard to analgesic use, 
there was a significant group difference between people with and without clinically relevant 
symptoms of disinhibition. 
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19 (22.4%) of the people who were reported to have clinically relevant CSDD score used 
analgesics regularly. In comparison, 33 (18.6%) participants without clinically relevant CSDD 
score used analgesics. 15 (24.6%) people with clinically relevant CMAI score used analgesics 
regularly, compared to 38 (18.4) without clinically relevant CMAI score. There were no 
significant results from the Chi-square test, meaning there was no group difference within 
CSDD or CMAI. 
 
Table 3.10 describe if there is an association between the use of analgesics and dementia 
symptoms (cognitive: MMSE; BPSD: NPI domains, CSDD, CMAI). Binominal regression is 
used to obtain RR, while logistical regression is used to obtain OR.  
 
Table 3.10 Association between regular use of analgesics and dementia symptoms, N = 280a 
 Crude Adjustedb 
 RR p-value  OR p-value 
(0.05) 
RR p-value  OR p-value 
(0.05) 
MMSE 1.005 r 
0.033 
0.887 1.006 r 
0.041 
0.887 1.006 r 
0.033 







0.918 1.007 r 
0.067 
0.914 1.012 r 
0.051 







0.053 1.097 r 
0.053 
0.056 1.064 r 
0.039 
0.087 1.093 r 
0.055 
0.078 
NPI anxiety 1.022 r 
0.039 
0.575 1.029 r 
0.051 
0.565 1.022 r 
0.039 







0.010 1.159 r 
0.031 
0.040 1.090 r 
0.051 
0.063 1.181 r 
0.090 
0.029 
CSDD 1.038 r 
0.023 
0.093 1.047 r 
0.031 
0.122 1.037 r 
0.023 
0.100 1.054 r 
0.033 
0.088 
CMAI 1.013 r 
0.013 
0.326 1.016 r 
0.017 
0.358 1.018 r 
0.013 




a Numbers deviates from 280 participant due to missing values. 12 people did not answer any questions for NPI-
12 total, 15 people for CSDD and 12 people for CMAI. CSDD: 3 answerers was excluded since they answered 
less than 80% of the CSDD domains.  
b Adjusted for age, sex and MMSE score 
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Out of the assessment scales for dementia symptoms, only NPI disinhibition had a significant 
associations (except risk ratio (RR) for adjusted regression). The crude odds ratio (OR) were 
1.159 (standard deviation 0.031), meaning the odds for using analgesics increased with 1.159 
(16%) times when NPI disinhibition score increased with one point. Adjusted OR was even 
higher (Adjusted OR 1.181 r 0.090). The risk ratio was at 1.108 (standard deviation r  0.044), 
meaning the risk for using analgesics increased with 1.108 (11%) times when NPI disinhibition 
score increased with one point. The other NPI domains were not significant, however crude 
NPI depression was at the threshold with a p-value of 0.053, however the adjusted regression 
yielded a non-significant result.   
  
The association between analgesic use and CSDD was not significant, however it was not far 
from a significant result for adjusted OR (crude OR 1.05, 95% CI 1.00 – 1.11, p = 1.122; 
adjusted OR 1.05, 95% CI 0.99 – 1.12; p = 0.088). Also here, the odds for using analgesics 
increased when CSDD score increased with one point. However, the 95% CI showed that the 
odds could change between -0.01% – 12% when adjusted for age, sex and MMSE score. The 
results from CMAI was not significant. 
 
The last table, table 3.11, describes the association between daily doses of analgesics and 
dementia symptoms (cognitive and BPSD). The coefficient explains how much the daily doses 
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Table 3.11 Association between individual daily doses (ID) for regular use and dementia 
symptoms, n = 44a  
Abbreviations: Coef, Coeficient; CI, Confidense Intervall; NPI, Neuropsychiatric Inventory; CSDD, Cornell 
Scale for Depression in Dementia, CMAI, Cohen-Mansfield Agitation Inventory   
a The numbers do not add up to 55 (participants who uses analgesics) because of incomplete data for ID 
b Adjusted for age, sex and MMSE 
 
A total of 44 (80.0%) out of the 55 participant who used analgesics regularly had disclosed 
their daily doses. Crude NPI depression is the only variable that yielded a significant 
association (p-value 0.044). The estimated coefficient show that the daily dose of analgetic 
increased with 0.014 points when the NPI depression score increased with one point. The 
change is relatively small and would not have an impact on the NPI depression score. The rest 
of the variables had small coefficients that would not had significant effect on the daily 








 Crude Adjustedb 
 Coef 95% CI p-value 
(0.05) 
Coef 95% CI p-value 
(0.05) 
MMSE -0.054  -0.016 - 0.005  0.303 -0.005  -0.015 - 0.005 0.351 
NPI 
agitation 
-0.004  -0.021 - 0.013 0.634 -0.006  -0.024 - 0.012 0.532 
NPI 
depression 
0.014  0.0004 - 0.027 0.044 0.011 -0.003 -  0.025 0.114 
NPI anxiety  0.001  -0.012 -  0.014 0.906 0.001 -0.012 -  0.015 0.885 
NPI 
disinhibition 
0.003  -0.018 - 0.023 0.804 0.005 -0.016 – 0.027 0.617 
CSDD 0.007  -0.001 - 0.015 0.075 0.007  -0.002 - 0.015 0.111 
CMAI 0.002  -0.002 - 0.007 0.289 0.002  -0.002 - 0.007 0.355 
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4. Discussion 
4.1 Method discussion  
4.1.1 Study population 
This thesis was based on the baseline data material from the LIVE@Home.Path study. First and 
foremost, the findings of this thesis reflects the selection of participants. The participants were 
mostly referred from the geriatric outpatient clinics, memory teams and the municipal home 
health services (22). There is a possibility that the study population had more health issues and 
used more medications than the general population of home-dwelling PWD. A minority of the 
participants, however, were recruited from outside the health care system. If more participants 
were recruited from the general public, for instance via referral from general practitioners, the 
data material may have reflected the analgesic use and dementia symptoms better for this 
demographic.  
 
In addition, the study included dyads of PWD and their informal caregiver (22). This causes a 
limitation in the study, where PWD with little to no contact with a caregiver were excluded 
from participating in the trial.  This could have altered the results, since they would most likely 
be more healthier if they did not have regular contact with a caregiver. However, it could be an 
issue receiving meaningful answers (96). PWD can struggle with their memory and the 
cognitive impairment could interfere with their ability to reflect over their situation. By having 
the informal caregiver answer some of the assessment as a proxy observer, the answers would 
most likely be closer to reality than if the person with dementia answered alone. For instance, 
it would be more challenging receiving the correct medication lists and the person with 
dementia might not realize that they displayed signs of BPSD. 
 
The baseline characteristics of the study population are in line with other studies reporting on 
the general population with dementia. The distribution for gender among the general population 
with dementia was estimated to be around 59.4% for women and 40.6% for men in Norway in 
the prevalence report by Gjøra et. al. (4). This is relatively similar to the gender distribution in 
our study population, which was at 62.6% for women and 37.4% for men (Table 3.1). Age 
distribution is also an important characteristic. The same report from Gjøra et al. showed that 
the prevalence of dementia cases almost doubled for each five-year period, from 5.6% (70-74 
years) to 48.1% (90+) (4). Naturally, participants in our study includes all age groups. 18.1% 
of the study population were within the youngest age group (65-74 year), 44.2% were in the 
75-84 age group and 37.7% were in the 85+ age group (Table 3.1). The age distribution was 
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diverse and representative for the general population. The distribution of people with different 
cognitive state was approximately evenly divided between people with mild (52.7%) and 
moderate (46.6%) cognitive impairment. The last three variables had a mostly even distribution. 
Around 50% of the participants had polypharmacy, which is around the average for elderly 
people in the Western world (19-21). 51.8% of the participants had not had a medication review 
with their GP in the last 6 months. The living situation among the study population was also 
divided into two equal parts, with 48.1% living alone and 51.9% lived with someone (partner, 
child, or other). Other studies have found similar results. One register-based study of the entire 
population in Denmark reported that 57 % of home-dwelling people with dementia lived alone, 
while another study from Germany reported that 51% lived alone (67, 97).  
 
4.1.2 Data gathering 
The second factor that have affected the result in this paper was how the data material was 
gathered. 2 study personnel visited the person with dementia (PWD) at a time. This was a 
strength for the trial. Having two study personnel ensured that the interviews could be 
conducted simultaneously, which shortened the interview time. Some people with dementia 
were looked after for most parts of the day by their caregiver, in order to protect them from 
potentially dangerous situation. Having a study personnel looking after the PWD while the 
caregiver was interviewed, ensured the safety of PWD and the caregiver could feel more 
comfortable staying away from the PWD for a longer period of time. This could lead to more 
thorough information provided in the caregiver interview.   
 
Going on home visits had also some strengths and weaknesses. Some people with dementia 
might feel more comfortable to talk in a familiar setting, such as their home, and can also 
minimize the power hierarchy between the PWD and study personnel (98, 99). By being in a 
familiar place, it can possible reduce the feeling of stress and anxiety for the person with 
dementia.  There is a possibility that when PWD feel stressed and anxious, it can make their 
memory become worse. This can again effect MMSE score and make it difficult to get 
meaningful answers during the interview (100). Therefore, a home visit could be positive for 
the assessments.   
 
A result that could have been effected negatively of home visits are MOBID-2 scores. If the 
person with dementia had to come into a clinic or other location, they would have had to move. 
It is possible that people with musculoskeletal pain or other pain would have experience more 
Amina Abdirahman Sheikh                                                                                  
 51 
pain, which would affect the MOBID-2 scores (101). Some caregivers could also feel 
uncomfortable  giving negative information about the person with dementia while being at the 
same house, such as the proxy ratings of BPSD symptoms. This could lead to an underreporting 
of symptoms from the caregiver.  
  
4.1.3 Medication list 
Understanding how the medication lists were provided is crucial for interpreting the findings 
presented in this thesis. The following paragraphs will elaborate on this regarding both regularly 
used medications and PRN.  
 
The information was for the most part obtained directly from PWD with help from their 
caregiver if necessary. This could lead to a systematic source of error, where the participants 
might over-or underreport how many medications they used. Some participants confirmed their 
medications with written medication lists from their personal health registers. This provided 
medication lists could have some strengths and weaknesses. The strength was that it minimized 
the risk of the participants underreporting the medicinal use. However, this principally regarded 
for regularly scheduled medicines. For PRN use of medication, the medication lists from the 
health registers could lead to an overreporting of medications in use. PWD who receive 
medication distributed from home nursing services cannot be given medications PRN without 
it being prescribed to the participants (102). Therefore, the participants who received 
medication from home nurses could have been registered with PRN prescriptions that were 
seldom or never used. This could be relevant for PRN use of paracetamol, which 29 people 
were registered using and stood for over half of the PRN use. In order to minimize the risks for 
overreporting of PRN use, all regression analyses were restricted to analgesic prescriptions for 
regularly scheduled use as an outcome. This creates a limitation in the thesis, where association 
between analgesic use and dementia symptoms cognitive function (MMSE), pain (MOBID-2 
score; MOBID-2 locations) and BPSD (NPI-12 total score; NPI domain score; CSDD; CMAI) 
only applies for regular analgesic use.  
 
The individual doses were calculated based on the DDD for each analgesic. However, when 
using the DDD as a dependent variable in the regression analyses, the data were not stratified 
according to analgesic class. An example is weak analgesic paracetamol and strong opioids. 
Many participants used the full DDD of paracetamol, meaning that they had a score of 1. People 
with strong opioids would more often use half of the DDD, meaning they had a score of 0.5. In 
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the analyses, the paracetamol user appears to receive a higher analgesic dose. This is 
problematic because the different analgesics are not directly comparable in terms of potency 
and safety. This approach was chosen for the analysis because it was still of interest to see if 
PWD who used higher doses if they had less BPSD symptoms (Table 3.11).   
 
If the data material for this study came from the Prescription Intermediary (PI) instead of the 
study population recruited in LIVE@Home.Path, the results could have changed for this study. 
The PI could give information about prescriptions for the entire Norwegian population, which 
gives larger data material to work with. The added information could explain what kind of 
analgesics people with dementia used compared to smaller study population. Some examples 
could be if the fraction of paracetamol used was as high as found in PWD participating in 
LIVE@Home.Path, or if more PWD used weak opioid. However, there were strengths 
gathering information from smaller study population. An issue with gathering data material 
from PI would be separating analgesic prescriptions for people with dementia. The analgesic 
prescription would have to be paired with a prescription that is connected to dementia. Not all 
PWD uses anti-dementia drugs because of side effects or because they have no effects, such as 
for people with PD and vascular dementia (103). Therefore, the data material collected in such 
manner would be generalizable only to people receiving anticholinesterase inhibitors or 
memantine. Another issue would be that the data material from the PI would not be able to 
separate people with different cognitive function. The smaller study population enabled the 
study personnel to test the participants’ cognitive function via MMSE test. This information 
made it possible for this thesis to give results for analgesic use based on cognitive function.  
 
4.1.4 Assessment scales  
The MMSE test is one of the most used assessment tools for cognitive function in dementia for 
its brief and simple design. The test can be conducted in under 5 minutes and consist of a wide 
range of questions connected to cognitive functions. However, the method has several 
important weaknesses. Results have been criticized for being biased towards lower scores in 
people with lower education who might have issues with the language or the mathematical 
questions in the test; and similarly the test may overestimate cognitive function in people with 
higher education who may achieve high scores despite a manifest decline from previous level 
of cognitive functioning. There is also a bias against people with visual impairments (75). The 
limitations could make dichotomization of the MMSE-variable more inaccurate, since people 
with higher cognitive function could get lower scores. Further on there are a lack of questions 
Amina Abdirahman Sheikh                                                                                  
 53 
that can address decline in some cognitive delays, especially visuospatial cognitive function  
(75).  
 
MOBID-2 is a good tool towards assessing pain intensity for people who have musculoskeletal 
pain in nursing homes (89). It is also a good method for visceral pain. The method is validified 
through checking for reliability and validity.  However, MOBID-2 does not address neuropathic 
pain, which is a limitation (89). In addition, the method does not address if the PWD is having 
acute or chronic pains, but focuses on pain within the last week (89). This limitation can be 
problematic, since people who experience pain might not feel pain at the time of examination. 
It can lead to a risk of underreporting pain, since the test score is dependent on when they are 
being tested. Some participants might experience pain of varying intensity during different parts 
of the day, or intermittent pain that can come and go (104). 
 
The MOBID-2 cut-off points are set by researchers in order to categorize the participants in 
two/three groups.  They do not reflect directly if the participants experience the location as 
significantly painful when pain severity is ≥ 3 (91, 92).  
 
During the MOBID-2 assessment, the person with dementia went through the assessment alone 
with the study personnel. The MOBID-2 assessment is validated when administered by or in 
the presence of a formal caregiver who is familiar with the PWD (92). This is important for 
several reasons. In Part I of the pain assessment, which involves active mobilization to assess 
musculoskeletal pain during movement, the caregiver should observe and interpret deviations 
from the person’s normal behavior, vocalizations, posture, and facial expressions as potential 
expressions of pain and pain intensity. This requires a high degree of familiarity with the person 
being assessed. The study personnel were not required to have had extensive contact with the 
PWD before conducting the pain assessment. Furthermore, in Part II, history of pain intensity 
experienced in other body parts and organs within the last week is assessed. This information 
was only available to the study personnel via self-report from the PWD because of the study 
procedures during data collection (with the informal caregiver unavailable in a separate room) 
and because of the relationship with no required previous contact between the study personnel 
and the PWD. Because the MOBID-2 assessment from the LIVE@Home.Path trial was more 
reliant on self-report from the PWD compared with the standard validated procedure, there is a 
risk that the MOBID-2 score underestimated pain intensity in the current study because of 
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problems with recollecting, interpreting, and verbally expressing symptoms of pain, and 
translating them to a 0-10 numeric rating scale.   
 
The EQ-5D-5L scale (pain/discomfort item) is a simple scale that is design for people to assess 
their own pain and many people with mild to moderate pain can still explain their pain (93, 
105). This is a strength to the study to have two assessment scales to report pain, either by self-
report and through proxy-rating. However, for people who have language issues or struggle to 
reflect over their pain, they can end up giving unreliable answers that can affect the EQ-5D-5L 
scores (26, 93). This is the reason why the analyses were performed with MOBID-2 scores.  
 
Agitation was measured through NPI agitation score and through CMAI score. There were 
fewer participants who were reported to have clinically relevant agitation in NPI agitation 
compared to CMAI. A reason could be that CMAI is a more extensive assessment tool for 
agitation assessing the frequency of 29 specific agitated behaviors (86), in contrast to the more 
generally phrased NPI agitation assessment which only exemplifies a few types of agitated or 
aggressive behavior (Appendix 3). When I conducted interviews, there were several caregivers 
that reacted negatively to the NPI agitation assessment and answered no, because the question 
included the word “aggression”. For the CMAI assessment, the specific symptoms were 
separated and the same caregivers could answer yes for several types of agitated behaviors 
(Appendix 3). This was especially apparent among the caregivers who were spouses/partners.  
 
The same principle applied in the depression assessment with NPI depression and CSDD. The 
CSDD assessment scale is more extensive with 19 questions, catching more people with 
depressive symptoms (82). And some caregivers were hesitant to describe the person with 
dementia as depressed and answered no for the categorical NPI depression item. While in the 
CSDD assessment, none of the questions use the term “depressed” except for the last one 
(Appendix 3). Both spouses and children of the person with dementia seemed to have this 
reaction. Based on these observations, it is more likely that NPI domain scores were 
systematically scored lower than the corresponding CMAI and CSDD scores. 
 
There are still strengths with NPI-12. One is that the method allows the caregiver to give a 
proxy-rating over 4 weeks. It can be difficult to assess behavioral and symptomatic changes 
over a short period of time, which makes this test a good choice. Another strength is that it 
testes neuropsychiatric symptoms on a broader way, including different symptoms. The test 
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yields both general and individual scores for different symptoms, which makes the test more 
universal for BPSD (79). 
 
Overall, the data quality is high since we are using different assessments scale to examine 
important issues for PWD; pain, agitation and depression.    
 
4.1.5 Statistical methods  
The variable “number of medication” was tested with Chi square test to see if there was a 
significant group difference between people with few or many medicines and the use of 
analgesics. There was an issue in the premise for the test, since people with no medication could 
not possibly use analgesics. This could lead to a false significance level, since using medicines 
would always be associated with using analgesics. This had been taken into consideration when 
conducting the test. There were 22 people who used no medicines, compared to 258 participants 
who used at least one medicines. In addition, there was a relatively large difference in the use 
of analgesics between people who used 1-4 medicines (9.4%) compared to people who used ≥ 
5 medicines (31.2%). It was unlikely that removing the group from the analysis would have 
change the p-value substantially and was therefore included in the analysis.  
 
A limitation in the data set was missing data. We chose to deal with missing data by only 
accepting BPSD scores (NPI-12 total score; CSDD; CMAI;) into the analyses when caregivers  
had provided answers for at least 80% of the domains or items/questions. This was done to 
prevent artificially low BPSD scores caused by insufficient registration. There were few 
participants that were cut because of this criterium. Most of the missing BPSD scores were not 
included because the participants had not answered any of the domains connected to the BPDS 
scores.  
 
4.2 Result discussion 
4.2.1 Characteristics 
To summarize, there was a significant difference in regular use of analgesics for gender, age 
group and the number of analgesics. 23.6% of women used analgesics compared to 13.5% of 
men. More people from the older age groups used analgesics, and more people who had 
polypharmacy used analgesics. Two studies looking at regular analgesic use found the same 
trends for gender, age and polypharmacy  (68, 69). 
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4.2.2 Prevalence and type of analgesics  
To summarize, 55 (19.6%) of the study population were prescribed analgesics regularly. It was 
divided between 13 (4.7%) participants using opioids, 9 (3.2%) participants using NSAIDs and 
41 (14.6) using paracetamol regularly. Including people with PRN analgesics, 90 people 
(32.1%) of the study population were prescribed with regular and/or PRN analgesics.  
 
Few previous studies have reported whether the participants used analgesics regularly. A 
register-based study from Finland looked at all purchased and reimbursed (for chronic use) 
analgesics from PWD (N = 67 215), and the researchers reported that 34.9% had purchased at 
least 1 analgesic within a 180 day period (68). One study from France showed that 13.1% of 
the participants used analgesics regularly (69). However, more studies from different countries 
are needed to understand the prevalence and pattern of regular and sporadic/intermittent 
analgesic use in community-dwelling elderly people with dementia.   
 
There was a relatively low prevalence of opioid use among the study population in the 
LIVE@Home.Path trial, with only 4.7% stating they used opioids on regular basis (Table 3.2). 
Looking closer at the types of analgesics, over half of the opioid prescriptions were transdermal 
patches (TDP) with the strong opioids buprenorphine (6 people) and fentanyl (3 people). The 
register-based study from Finland reported that 7.2% had used opioids within a 180 day period 
(106). It further states that the participants used more mild opioids than strong analgesics. 
However TDP with buprenorphine and fentanyl were used more frequently by PWD compared 
to people without dementia (68).  Another register-based study in Denmark supports these 
findings, were home-dwelling PWD used more TDP with buprenorphine and fentanyl 
compared to people without dementia (67).  The opioid use varies from region to region, so the 
opioid use in LIVE could be representative or not.    
 
Only a small fraction of the study population used NSAIDs regularly (3.2%) and half of them 
used glucosamine (Table 3.2 and Table 3.3). In comparison, Gallini et al. reported 4.0% use of 
NSAIDs (69). And according to the register-based Finnish study, 13.3% of home-dwelling 
PWD used NSAIDs. An interesting finding from the study was that people diagnosed with 
dementia in 2005 were more likely to be prescribed with NSAIDs compared to people 
diagnosed in 2012. This indicates that prescribers have become more aware of the potential 
hazards associated with NSAID use in elderly people, leading to a corresponding change in 
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prescribing practice (68). This development could explain why so few participants in the LIVE 
trial used NSAIDs.  
 
Paracetamol was the most commonly used analgesic, with 14.6% stating they used the analgesic 
on a regular basis (Table 3.2). Previous studies have also reported that paracetamol was the 
most frequently used analgesic, however the prevalence was more diverse. Haasum et. al. 
reported that 18.8% of home-dwelling PWD (N = 119) used paracetamol on a regular basis 
(65), Gallini et. al. reported 8.7% of the study population using paracetamol (69), while Hamina 
et. al. from the Finnish register-based study reported 25% of PWD using paracetamol (68). 
Based on previous studies, it seems that the use of paracetamol among the study population 
from the LIVE trial is on the lower side of expectations.  
 
The result from Table 3.2 shows that 3.2% of the participants used 2 or more analgesics 
regularly. With PRN use included, the total number of participants using 2 or more analgesics 
is 3.9%. Other studies have a wider range in result, from 6.8% reported by Hamina et al. to 20% 
reported by Barry et al. (35, 36, 68). The study from Hamina et. al. is register based and does 
not include over the counter (OTC) prescriptions. Therefore, the use of multiple analgesics 
might be higher (68). Based on these studies, there are relatively fewer people than expected in 
the current sample that use multiple analgesics. 
 
Other studies have shown shows similar results in analgesic prescribing for regular and/or on-
demand use for home-dwelling people with dementia. Haasum et. al. reported that 36.1% of the 
study population, consisting of home-dwelling PWD in Sweden (N = 119), used analgesics 
regularly and/or PRN. One study in Northern Ireland reported that 40% of the study population 
(N = 77) used prescribed or over-the-counter (OTC) analgesics. In Finland, Mantyselka et. al. 
reported that 33% of the home-dwelling study population with dementia (N=75) used 
analgesics to ease pain, which can be interpreted as regular and on-demand use (63). These 
studies show the analgesic prescribing was at around 33-40%, which is close to the findings 
from this thesis, which was 32.1%.  
 
4.2.3 MMSE score and analgesic use  
The analgesic use among the study population showed that people with higher MMSE score 
generally used more analgesics (Table 3.4, Table 3.5). This association applied to both regular 
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and PRN use for all analgesic classes, however the difference was not significant (p-value > 
0.05).  
 
Table 3.5 showed that 29 (20.9%) people with mild dementia (MMSE score ≥ 21) used 
analgesics regularly, compared to 24 (19.5%) people with moderate dementia (MMSE score ≤ 
20). The difference in the number of participants using analgesics is small between people with 
mild and moderate cognitive impairment. However looking at Table 3.4, there are more 
participants with mild cognitive impairment that uses analgesics. This is because more people 
with mild dementia uses multiple analgesics, as opposed to the participants with moderate 
dementia. The difference in use of analgesics was mainly observed for opioids and NSAIDs. 
Participants with mild dementia used more opioids and NSAIDs, regardless of prescription 
type. Paracetamol was used more evenly between people with mild and moderate dementia on 
a regular basis. However more people with mild dementia used paracetamol PRN compared to 
people with moderate dementia (table 3.4).  
 
In regards to analgesic use, the group differences between people with mild and moderate 
cognitive impairment was not significant (p-value > 0.05). There could be factors that could 
have contributed to the non-significant results, such as small data set for opioid (9 people) and 
NSAIDs use (6 people) (Table 3.3). Other studies had not found an association between 
analgesic use and MMSE score. The study from Barry et. al. had checked for association and 
come to the same conclusion. It is important to note that the study population was small (N=77) 
(36).  
 
4.2.4 Analgesic use according to pain 
To summarize, 40 (14.8%) participants in the study population were reported to have clinically 
relevant pain (MOBID-2 score ≥ 3), while 86 (32.0%) participants were assessed to have at 
least one location with clinically relevant pain (Table 3.6). Around half of the participants who 
had clinically relevant pain were not registered with regularly scheduled analgesics. In 
comparison, around 13-16% of the participants who were reported to have little to no pain used 
analgesics regularly according to the different pain variables.  
 
The scores from the EQ-5D-5L (item pain/discomfort), and MOBID-2 were similar, indicating 
that the study group had a high capability of expressing pain. However, there were some 
discrepancies. There were more participants (15 people) that had self-reported strong to very 
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strong pain through EQ-5D-5L. In comparison, 5 people were reported to have severe pain 
during the MOBID-2 assessment by study personnel. Furthermore, 218 participants self-
reported no to little pain through EQ-5D-5L, while 231 participants were reported to have no 
to mild pain in the MOBID-2 assessment. Even though the two scales are not directly 
interchangeable, it is still apparent that more PWD self-report pain compared to the proxy 
ratings from study personnel. This was a surprising finding, since there was a concern that PWD 
could not express their pain to family or healthcare personnel as a consequence of the cognitive 
impairment (28).  
 
Another interesting find was that for the pain variables (EQ-5D-5L; MOBID-2; MOBID-2 
locations), around half of the participants with clinically significant pain did not use analgesics 
regularly. For MOBID-2 scores, 57.1 % of people with moderate pain (score 3-6) and 60% with 
severe pain (score ≥ 7) did not use analgesics regularly. It is likely that some of them used 
analgesic as needed. In addition, there were few participants with severe pain, which makes the 
results for analgesic use more unsure. However, these results still indicate that some of the 
participants are not receiving adequate pain management. Also for MOBID-2 locations, people 
not receiving regular analgesics ranges from 81.4% for 1 clinically painful location, to 33.3% 
for 7 clinically painful location (Table 3.6). There seems to be an increasing chance for 
analgesic treatment as the participants have multiple painful locations. However, the data set is 
small for people with multiple painful locations. In order to conclude this connection, there 
needs to be done more research regarding painful locations and analgesic use.  
 
Another concern was that PWD had untreated severe pain, because untreated pain can lead to 
negative consequences for PWD. There were few participants that had reported having 
strong/severe pain (5 people for MOBID-2 score; 15 people from EQ-5D-5L). The low number 
of people with strong/severe pain could explain why there were few participants having 
prescriptions for opioids. It also indicate that there was not a general need for participants to 
use stronger analgesics. And even though around half of them did not use analgesics regularly 
as explained earlier, they only accounted for 3 people (MOBID-2) and 7 people (EQ-5D-5L) 
of the study population.  
 
The 𝜒 2 - test showed that for analgesic use, there was a significant group difference between 
people with no/little pain and people with clinically relevant pain (p < 0.001). This was also 
applicable to the number of clinically relevant painful locations, where more people with 
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multiple painful locations used analgesics compared to people without painful locations. 
Furthermore, the was a significant association between the use of analgesics and MOBID-2 
score. The odds ratio was significant both for crude OR (1.49, 95% CI 1.25 – 1.78), and for 
adjusted OR (1.50, 95% CI 1.25 – 1.80) (Table 3.7). The relative risk showed the risk for using 
analgesics increased by 23% when the MOBID-2 score increased with 1 point. Even when RR 
was adjusted for age, sex and MMSE reduced the risks to 22%, it still showed that participants 
used more analgesics according to the pain severity.  
 
4.2.5 Dementia symptoms and analgesic use  
To summarize the results, checking for association between having pain and having different 
dementia symptoms (cognitive: MMSE; BPSD: NPI domain, CSDD, CMAI) generally yielded 
non-significant results. There were many participants that had clinically relevant BPSD 
symptoms (NPI-12: 152 people; CSDD: 85 people; CMAI: 61 people). However, no significant 
association between analgesic use and dementia symptoms were detected except for the NPI 
disinhibition item which was significantly associated with analgesic use.  
 
A linear regression was performed to check for association between pain (MOBID-2 score) and 
dementia symptoms. The reason was to see if the participants with pain also had dementia 
symptoms, which could support the theory that BPSD could be an expression for pain among 
PWD (45, 46). However the regression showed there was no significant association between 
pain and MMSE score, NPI domains (agitation, anxiety, depression), CSDD or CMAI (Table 
3.8). This meant that people with more dementia symptoms were not reported to have 
significantly more pain through the MOBID-2 score.  
 
There were many participants that had BPSD. Depression was a prevalent symptom, with 58 
(21.7%) participants having clinically relevant NPI depression score. The CSDD assessment 
yielded even more participants with clinically relevant depressive symptoms (85 people, 
32.4%). Borsje et. al. conducted a systematic review of BPSD signs among home-dwelling 
PWD in 2015 (107). They reported that other studies had a prevalence of 10% to 42% for 
depression. In addition, a Norwegian study reported that 32.1% (N = 720) had depressive 
symptoms (CSDD ≥ 7), so the prevalence in the LIVE- study group is similar to these studies 
(108). Agitation/aggression, an important BPSD sign that had previously been linked to pain 
expression (45, 46), were less prevalent compared to other studies. According to Borsje et. al. 
other studies had reported a prevalence of 18% to 62% for agitation (107). There were relatively 
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few people who had clinically relevant NPI agitation score (24 people, 9.0%). However, 61 
(22.8%) participants had clinically relevant CMAI scores. It is still on the lower end of what 
previous studies have reported. NPI anxiety score was clinically relevant for 53 (20.1%), which 
was similar to other studies that had reported a prevalence of 18-24% (107).  
 
The different analyses for analgesic use and dementia symptoms were for the most part not 
significant. The 𝜒 2 – test showed in regards to analgesic use, there were no significant group-
differences between people with and without the different BPSD variables. The only exception 
was for NPI disinhibition, were significantly more people with clinically relevant disinhibition 
used analgesics compared to people without disinhibition. (Table 3.9). For the other BPSD 
variables, the analgesic use was almost the same for people with and without BPSD symptoms. 
(Table 3.9). Associations between analgesic use and BPSD was also not significant except for 
disinhibition, both crude and adjusted regressions. In addition, analgesic use was also tested for 
association to cognition (MMSE) and was also not significant (Table 3.10). The regression 
between individual daily dosages and dementia symptoms were also not significant for any of 
the variables (Table 3.11).  
 
The results from the analyses of dementia symptoms could be explained by the results from the 
regression between MOBID-2 score and dementia symptoms (Table 3.8). If analgesic treatment 
is supposed to reduce BPSD symptoms, then the BPSD symptoms has to be connected to pain. 
As explained earlier, there was no association between increasing BPSD scores and MOBID-2 
scores. Therefore, it would have been unlikely that analgesic treatment had an effect on BPSD.  
 
4.2.6 Future studies  
Future studies should further investigate what type of analgesics are used among home-
dwelling PWD according to their cognitive function in Norway. Because there were few 
participants who used opioids and NSAIDs in the LIVE study population, the analyses could 
not find a significant difference between analgesic use and dementia symptoms. Furthermore, 
there should be more studies assessing whether or not pain leads to dementia symptoms among 
home-dwelling people. Previous have indicted that agitation and depression has been linked to 
pain (43). Even though this study has not found significant association between pain and BPSD, 
there need to be more research to further investigate this link.  
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5. Conclusion  
In this study, 19.6% of the study population used analgesics regularly. There were few people 
in the study group that used opioids and NSAIDs. Around half of the participants who had 
significant pain received regular analgesic treatment, however there were few participants with 
severe pain. BPSD symptoms were prevalent among the study population, especially 
depression and anxiety, however there was no significant association between BPSD and pain. 
Lastly, this study did not find significant associations between analgesic use and cognitive 
status or BPSD symptoms, except higher rates of analgesic use among those with symptoms of 
disinhibition which warrants further investigation. However, multiple testing correction has not 
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Personen med demens  
Hvordan starte kartleggingen? 
Vi anbefaler at to personer deltar i baselinekartleggingen, da situasjonen er ny for alle 
deltagere og samtykke skal innhentes, i tillegg til essensiell informasjon om både personen 
med demens og pårørende skal kartlegges. 
Den første delen av spørreskjemaene til personen med demens bør fylles ut i samarbeid med 
pårørende. At pårørende er til stede sammen med personen med demens i begynnelsen kan 
bidra til å ufarliggjøre situasjonen for personen med demens, og vil i tillegg gi bedre og 
sikrere informasjon. Vi anbefaler at pårørende er med i utfyllingen av alle momenter til og 
med RUD (Helseøkonomisk spørreskjema), og ved behov ved kartleggingen av 
velferdsteknologi og frivillighet (utvis skjønn). Vi har markert gjeldende verktøy med 
understrekning i denne manualen. Resten av innsamlingen bør gjøres i separate rom.  
Blodtrykksapparat, vekt og stoppeklokke (el.) kreves for kartlegging av fysiske observasjon. 
Obligatoriske spørsmål er markert med * i de elektroniske spørreskjemaene.  
Tips: Dersom du får feilmelding når du logger deg på med deltagers passord, sjekk om du fremdeles er 
innlogget med en annen bruker (pasientnummer står øverst i høyre hjørne).  
Vi anbefaler at denne manualen tas med i papirform og kan brukes aktivt i kartleggingen. 
Bakgrunnsopplysninger 
Dersom det er kjent at personen med demens ikke anerkjenner denne diagnosen eller har 
vansker med å bruke dette ordet bør dette unngås. Man kan gjerne titulere personen med 
navn eller relasjon.  
- Bakgrunnsopplysninger: fødselsdato, kjønn, informasjon om demenssykdommen 
- Uheldige hendelser siste seks måneder (fall, vold etc) 
- Er medikamentgjennomgang gjennomført siste år? 
Sykdomsanamnese 
Her krysser man av om personen med demens eller pårørende vet om han/hun har disse 
sykdommene eller tilstandene. Undergrupper kommer opp dersom man sier ja.  
NB under andre sykdommer av betydning for aktuell tilstand: alternativene er kreftsykdom, 
KOLS, leddgikt (artritt), kronisk nyresykdom eller annen sykdom.  
Helseøkonomisk spørreskjema (RUD) 
Pasienten = Personen med demens.  
Endring i boform: for eksempel korttidsopphold i sykehjem, ØHD-senger etc. 
Korttidsopphold på sykehjem registreres som «Demenstilpasset botilbud» dersom det er i en 
demenstilpasset avdeling, «Annet» dersom korttidsoppholdet skyldes somatiske faktorer.  
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Skjemaet skiller mellom sykehusinnleggelse (mer enn 24 timer). Akuttmottak eller legevakt 
gjelder alle opphold under 24 timer. Tips: I praksis kan man spørre om de har overnattet på 
sykehus. 
Eksempel: 6 dager innlagt på sykehus hvorav 1 på generell medisinsk, deretter overflytting 
til intensiv avdeling med opphold 2 netter og deretter til geriatrisk avdeling Æ 1 
indremedisinsk, 2 Annet; spesifisert intensivavdeling, 2 geriatrisk avdeling.  
 «I løpet av den siste måneden, har pasienten blitt behandlet av lege, fysioterapeut, psykolog 
eller annet profesjonelt helsepersonell?» - innleggelser på sykehus gjelder ikke her. Med lege 
menes her også polikliniske besøk. Dersom personen med demens har vært innlagt på 
sykehus regnes ikke behandlingene gitt under denne fanen, da det omfattes av spørsmålene 
om sykehusinnleggelse lengre opp.  
Tjenester: Antall besøk de siste 30 dagene og varighet på disse registreres. Dersom 
vedkommende ikke mottar hjemmesykepleie, hjemmetjenester, matombringing, dagsenter, 
transporttjenester eller annet relevant lar man alle feltene stå åpne. Ved transport og 
matombringing registreres ikke tid per besøk. 
Eksempel: Dersom man har hjemmesykepleie x4 daglig som i snitt varer i 20 min og har hatt 
to ekstra besøk i løpet av den siste uken grunnet fall blir utfyllingen som følger: 4 besøk/dag 
x 30 dager + 2 ekstra besøk = 122 besøk, 20 min per besøk.  
Medikamentliste 
Fylles ut etter opplysninger fra pårørende og personen med demens. Noter det faktiske 
forbruket av medikamenter. Dersom hjemmesykepleie administrerer medikamentene kan 
man skrive inn listen som foreligger i elektronisk pasientjournal. Det kan være en fordel å 
undersøke dette på forhånd. 
Eventuell medikamentliste skrives inn som fritekst. Få med 
- Medikamentnavn (virkestoff eller merkenavn) 
- Administrasjonsform (p.o., sublingv, plaster, s.c., i.m. osv) 
- Hyppighet (skriv v/b om det er behovsmedikament) 
Tips: er det en lang liste medikamenter kan man gjerne gjøre ferdig spørreskjemaene og taste inn i 
etterkant. Det kan være fint å få se en medikamentliste. Skill medikamenter med komma eller 
skråstrek.  
Velferdsteknologi 
Velferdsteknologi er et bredt begrep. Dersom man krysser «Ja» på første spørsmål kommer 





Vi ønsker å kartlegge hvem som har kontakt med frivillige (og i så fall hvor ofte, hvor lenge 
man har møttes, hva man gjør sammen). Dersom deltager ikke har frivillige tjenester, 
kartlegges holdninger. Spesifiser og beskriv dersom nødvendig. Stikkordsform er 
tilstrekkelig. 
En frivillig er en person som gjør frivillig arbeid eller frivillig innsats av fri vilje. Dette er 
ulønnet innsats rettet mot personer utenfor egen famille eller husstand. Slik frivillig innsats 
kan både være organisert gjennom organisasjoner eller fremtre spontant og uorganisert, som 
når frivillig innsats gjøres av enkeltmennesker og grupperinger som ikke er del av de 
frivillige organisasjonene. 
NB: Avlastertjenesten i Bærum kommune regnes i denne sammenhengen ikke som frivillig 
tjeneste da de mottar lønn fra kommunen.   
 
MMSE  
Fyll inn MMSE i papirform i samarbeid med personen med demens. MMSE gjøres ved 
baseline, etter ett år og ved studieslutt. MMSE scannes inn til elektronisk pasientjournal etter 
lokal prosedyre. Hele MMSE utføres, men bare enkelt- og totalskår noteres elektronisk. 
Pårørende skal ikke være til stede ved testing. Obligatorisk skjema.  
Instruksjoner ved utfylling av MMSE: Noter faktorer som kan påvirke utførelse negativt, 
som for eksempel dårlige norskkunnskaper og sykdom i kommentarfeltet. Øvrige 
instruksjoner er gitt på testverktøyet levert av Aldring og helse.  
Ved retesting: For å redusere læringseffekt fra tidligere testing, bytt til riktig oppgavesett 
(ordsett og starttall) som spesifisert på oppgave 11–13. Dersom du ikke har kjennskap til at 
deltageren har gjort MMSE nylig gjennomføres alternativ A. Dersom du har kjennskap til at 
det er gjennomført utredning eller testing nylig velger du alternativ B eller C.  
Ved baselinekartlegging: om totalskåre er rett utenfor inklusjonskriterene inkluderes 
pasienten i studien allikevel (dagvariasjon kan være til stede). Dersom flere poeng skiller må 





Blodtrykk (mmHg), puls (slag/min) og vekt (kg) måles av kartlegger. Opplysninger om 
høyde noteres (cm). Alle felter er obligatorisk.  
Smertekartlegging (MOBID-2) 
Kartleggingsverktøy for smerter hos personer med demens.  
Smerteadferd relatert til muskulatur, skjelett og hud: Nåværende tidspunkt.  
Observer pasienten før du starter mobilisering. Forklar forståelig hva du vil gjøre. Led 
pasienten og gjennomfør bevegelsene med forsiktighet. Stopp dersom du registrerer 
smerteadferd hos pasienten.  
 
1. Hjelp/led til å åpne hendene  
2. Hjelp/led hendene mot hodet 
3. Hjelp/led til bøying og strekking av ankler, knær og hofteledd 
4. Hjelp/led til å snu seg i sengen til begge sider Tips: Spør om de kan reise seg dersom de 
sitter, ev legge seg nedpå sofaen dersom de sitter i en sofa.  
5. Hjelp/led til å sette seg opp på sengekanten Tips: Spør/vurder om de har vondt dersom de 
sitter. 
Ved bruk av papirskjema: tolk styrken av smerteintensitet og sett kryss på linjen. 0 tilsvarer 
ingen smerter. 10 er verst tenkelige smerter.  
Ved bruk av elektroniske skjema: dersom pasienten gir uttrykk for smerter; kryss «Ja» og 
skriv inn smerteintensiteten mellom 0 og 10. 
Smerteadferd relatert indre organer, hode og hud: Spør om de har hatt vondt den siste uken 
og baser skåringen på svaret og observert smerteadferd.  
6. Hode, munn, hals 
7. Bryst, lunge, hjerte  
8. Mage – øvre del  
9. Bekken, mage – nedre del 
10. Hud, infeksjon, sår  
Ved bruk av papirskjema: tolk styrken av smerteintensitet og sett kryss på linjen. 0 tilsvarer 
ingen smerter. 10 er verst tenkelige smerter.  
Ved bruk av elektroniske skjema: tolk styrken av smerteintensitet og skriv inn tall mellom 0 
og 10.  





Åpne med å si «Jeg vil nå stille deg noen spørsmål om din livskvalitet, og jeg vil at du skal 
svare med en av følgende ord: dårlig, noenlunde, god eller svært god». Pek på ordene i 
skjemaet mens du sier alternativene. Bruk gjerne ordlyden: «Hva synes du om ……? Synes 
du det er dårlig, noenlunde, god eller svært god?» Tips: Gi gjerne papirversjonen til 
deltageren og notér selv på elektronisk. 
Dersom to eller flere delspørsmål ikke kan besvares av deltageren kan man avbryte 
utspørringen og notere dette i kommentarfeltet. Pårørende skal vurdere egen livskvalitet og 
personen med demens’ livskvalitet med samme skjema. Samme instruksjon gjelder.  
Delspørsmål Tips  
Fysisk helse Hvordan har din fysiske helse vært den siste tiden? Vil du si helsen din er dårlig, 
noenlunde, god eller svært god? Velg det alternativet som passer best.  
Arbeidslyst Hvordan har arbeidslysten din vært? Hvordan har energinivået ditt vært? 
Dersom de svarer varierende, spør hvordan det har vært storparten av 
tiden over de siste dagene.  
Sinnsstemning Hvordan har sinnsstemningen din vært de siste dagene? Har du følt deg nedfor? 
Bosituasjon  Hva synes du om stedet du bor nå? Hvordan er din bosituasjon? 
Hukommelse Hvordan vurderer du din egen hukommelse? 
Familie Hvordan er relasjonen til dine nære familiemedlemmer? Dersom de svarer at de 
ikke har noen familie; spør mer spesifikt om barn, nevøer etc. Alle har en 
familie – det kan hende at du må ut i slektsleddene. 
Ekteskap  Hva synes du om ekteskapet ditt? Hvordan er relasjonen til … (navn på 
vedkommende)? Dersom deltager er singel, enke/enkemann eller skilt, spør 
man om relasjonen til den personen de har det nærmeste relasjonen til, 
enten familie eller venn. Dersom det er en person som gir omsorg i 
hverdagen spør man om forholdet til denne.  
Venner Hvordan er forholdet ditt til vennene dine? Vil du si det er dårlig, noenlunde, godt 
eller svært godt? Hvis de svarer at de ikke har venner, eller at alle vennene 
er døde, graver du videre. Har du noen du liker å være sammen med utenom 
familien din? Vil du si at den personen er en venn? Hvis de ikke har noen i det 
hele tatt, spør: Hvordan føler du omkring det at du ikke har noen venner? 
Seg selv  Hva synes du om deg selv, med alle de sidene av deg som utgjør deg? 
Huslige gjøremål  Hvordan vil du si at dine muligheter til ting du skal gjøre i huset eller andre ting 
du trenger å få gjort? Spør om konkrete, praktiske gjøremål de må gjøre i 
hverdagen.  
Fornøyelser Hvordan er mulighetene dine for å gjøre noe gøy?  
Økonomi  Hvordan er din finansielle situasjon/økonomi? Dersom deltageren nøler, 
forklar at du ikke er interessert i pengene, men hvilke følelser/holdninger 
de selv har. 
Livet som helhet Hvordan vil du beskrive livet ditt som helhet? 
Kommentar Dersom deltager ikke klarer å svare på et av emnene kan det noteres her. 
Feltet kan også brukes dersom det er særlige forhold som virker inn på 
vurderingen ved nåværende tidspunkt. Eksempler: nylig mistet førerkort, 




Spørreskjema om helse (EQ-5D-5L) 
Under hver kategori skal deltageren krysse av «DEN ENE boksen som best beskriver helsen 
I DAG». Det spiller ingen rolle om dagen i dag er usedvanlig god eller dårlig.  
For vurdering av «DEN SAMLEDE HELSEN I DAG» brukes VAS skala. Be deltageren peke 
på skalaen på den verdien som angir helsen i dag. Skalaen spenner fra 0 – den dårligste 
helsen deltageren kan tenke seg til 100 – den beste helsen deltageren kan tenke seg. Punktet 
som markeres av deltageren skrives inn i rubrikken i spørreskjemaet. Når dette gjøres 
elektronisk vises det laminerte spørreskjemaet til deltageren.  
Dersom deltageren ikke vil/ikke klarer å svare skal ikke svar noteres. Feltene står da blanke.  
General Medical Health Rating (GMHR) 
Fylles ut av kartleggeren som en helhetsvurdering – ikke involver personen med demens i 
denne. Derfor ligger denne langt bak i spørreskjemapakken. Rangeringen spenner fra dårlig 
til svært god. Veiledning til skåring er med i det elektroniske spørreskjemaet.  
Gradering Veiledende informasjon 
Svært god  Ingen nåværende ustabil somatisk sykdomstilstand, kan ha opptil to stabile 
somatiske sykdomstilstander, står på få (ikke mer enn to) medikamenter og 
fremtrer som frisk og i god helsetilstand. 
God Kan ha en ustabil somatisk sykdomstilstand som blir behandlet og/eller noen 
få (opptil fire) stabile sykdomstilstander, står på få (opp til fire) 
medikamenter og fremtrer bare som litt sykdomspreget. 
Moderat  Har mer enn en (ikke mer enn tre) ustabile somatiske sykdomstilstander, 
og/eller flere stabile, men kroniske somatiske tilstander, står på flere 
medikamenter og fremtrer som moderat syk  
Dårlig Flere ustabile somatiske sykdomstilstander, står på mange medikamenter, 




Bruk åpne spørsmål i samtaleform. Noter svarene stikkordsmessig. Kan være fint 





Helseøkonomisk spørreskjema (RUD) 
Hensikten med spørreskjemaet er å samle informasjon om ressursbruken for å kalkulere 
kostnadene til hver pasient og pårørende i helsetjenesten. I denne forbindelse er hensikten å 
finne ut om koordinatorrollen er gunstig i samfunnsøkonomisk perspektiv. Gjøres som et 
intervju med deltager.  
Del 1: Beskrivelse av hovedansvarlig omsorgsgiver: Fødselsdato og bakgrunnsinformasjon 
om bosituasjon etc er obligatorisk. Tips: Fødselsdato: trykk på 2019 – da kan du bla i årstall. 
Dersom du skriver dato inn manuelt må måned skrives inn først (mm/dd/yyyy). Forhold: 
Samboere registreres som ektefelle. Pårørendekurs er informasjonskurs til pårørende for 
personer med demens. Det spiller ingen rolle når dette er gjort eller hvor mange ganger man 
har deltatt. 
Del 2: Omsorgsgivers tidsbruk inndeles etter PADL, IADL og veiledning. Ved hvert punkt 
anslås hvor mange ganger aktiviteten er gjennomført den siste måneden. NB: Det er viktig å 
presisere at angitte total tidsbruk ikke kan overstige 24 t/døgn; vi har ingen sperrer i 
spørreskjemaet som oppdager om tidsbruk overstiger 24 t. Tidsbruk skal representere den 
siste måneden og skrives inn som antall timer og minutter. Fyll inn alle felter. Eksempel: 5 
timer & 0 min eller 0 timer & 40 min.  
Tips: Spør gjerne om de kan forlate huset og personen med demens klarer seg alene, og i så 
tilfelle: hvor lenge? Bruk også tiden de sover til å si noe om hvor mye de må være 
tilgjengelige (dersom de sover uforstyrret er maksimaltiden tilgjengelig for personen med 
demens 24 t minus antall timer med søvn)? Veiledning på telefon er viktig moment, spør om 
gjerne pårørende om dette.  
Eksempel: Personen med demens krever 45 min morgenstell og 30 min aftenstell daglig 
hvilket utgjør 1 time &15 min PADL daglig, krever hjelp til handling av matvarer a 1 
time&30 min to ganger i uka (IADL) og veiledning på telefon ca 0t&30 min i daglig.  
Del 3: Omsorgsgivers arbeidssituasjon  
Rett utdannelsesnivå velges fra menyen. Spør etter og fyll inn yrke og antall år i arbeid 
(ansiennitet).  
Inntektsgivende arbeid: Dersom pårørende har vært sykemeldt mer enn 4 uker regnes dette 
som «ikke i lønnet arbeid». Årsak til at man har sluttet i jobb/reduserte arbeidstiden 
spesifiseres. Dersom man har sluttet å arbeide for å pleie pasienten krysses det av for dette 
selv om vedkommende får lønn for dette. Når man skal anslå antall timer i jobb inkluderes 
eventuelt betalt omsorgstid – dette spesifiseres i spørreskjemaet. Tidsbruk skal representere 
den siste måneden og skrives inn som antall timer og minutter. Fyll inn alle felter.  
Eksempel: En ordinær arbeidsuke er 37 timer & 30 min. En 20% stilling tilsvarer 7timer & 30 
min/uke. En 80% stilling tilsvarer 30 timer & 0 min/uke.  
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Reduksjon i arbeidstid dekker planlagt reduksjon i arbeidstid som følge av personen med 
demens, til forskjell fra arbeidstimer tapt som dekker uforventede hendelser eller annen 
assistanse. Eks: dersom personen med demens har gått seg vill, dersom det er utløst 
trygghetsalarm, besøk på legevakt og lignende.  
Del 4: Pårørendes bruk av helsevesenets ressurser  
Innleggelse på sykehus: Innleggelse på sykehus som varer mer enn 24 timer siste måned 
regnes inn (altså med overnatting). Angi antall innleggelser, samt spesifiser antall netter på 
respektive avdelinger.  
Eksempel: Vedkommende var lagt inn på kirurgisk avdeling to ganger, der det ene 
oppholdet inkluderte fire netter og det andre i en natt. Dette registreres som to innleggelser, 
med fem dager på kirurgisk. Dersom vedkommende ble innlagt også en natt på geriatrisk 
avdeling i forbindelse med ett av oppholdene, registreres dette som to innleggelser med fem 
dager på kirurgisk og en dag på geriatrisk.  
Akuttbehandling i sykehus: Sykehusinnleggelser uten overnatting registreres her. Legevakt 
er ikke akuttbehandling i sykehus. 
Behandlet av lege/fysioterapeut/psykolog/Annet helsepersonell: Alle behandlinger/besøk 
skal registreres – også besøk på legevakt. Hjemmebesøk inkluderes. Registrer hvilket 
helsepersonell som har vært involvert. ØHD-opphold registreres under annet med en 
beskrivelse og antall besøk, samt antall netter totalt. La feltene stå tomme dersom 
yrkesgruppen ikke er oppsøkt. Kryss av dersom det ikke har vært kontakt med 
helsepersonell. 
Eksempel: Pårørende oppsøkte legevakt en gang etter fall, og er også i kontakt med 
fysioterapeut ukentlig, og konsulterer psykolog en gang i måneden. Respektive felter fylles 
ut (i dette tilfellet allmennpraktiker på legevakt x1, fysioterapeut x4, psykolog x1).  
Medisinliste 
Kryss av dersom ingen medikamenter brukes. Ved medikamentbruk skrives det inn som 
fritekst.  
- Medikamentnavn (virkestoff eller merkenavn) 
- Administrasjonsform (p.o., sublingv, plaster, s.c., i.m. osv) 
- Hyppighet (skriv inn v/b om det er behovsmedikament) 
Tips: er det en lang liste medikamenter kan man gjerne gjøre ferdig spørreskjemaene og taste inn i 
etterkant. Det kan være fint å få se en medikamentliste.  




Livskvalitet – pårørende rater sin egen livskvalitet (QOL-AD) 
Åpne med å si «Jeg vil nå stille deg noen spørsmål om din egen livskvalitet, og jeg vil at du 
skal svare med en av følgende ord: dårlig, noenlunde, god eller svært god». Pek på ordene i 
skjemaet mens du sier alternativene. Bruk gjerne ordlyden: «Hva synes du om ……? Synes 
du det er dårlig, noenlunde, god eller svært god?» Tips: Gi gjerne papirversjonen til 
deltageren og notér selv elektronisk. 
Dersom to eller flere delspørsmål ikke kan besvares av deltageren kan man avbryte dette 
spørreskjemaet og notere årsaken i kommentarfeltet. 
Delspørsmål Tips  
Fysisk helse Hvordan har din fysiske helse vært den siste tiden? Vil du si helsen din er dårlig, 
noenlunde, god eller svært god? Velg det alternativet som passer best.  
Arbeidslyst Hvordan har arbeidslysten din vært? Hvordan har energinivået ditt vært? 
Dersom de svarer varierende, spør hvordan det har vært storparten av 
tiden over de siste dagene.  
Sinnsstemning Hvordan har sinnsstemningen din vært de siste dagene? Har du følt deg nedfor? 
Bosituasjon  Hva synes du om stedet du bor nå? Hvordan er din bosituasjon? 
Hukommelse Hvordan vurderer du din egen hukommelse? 
Familie Hvordan er relasjonen til dine nære familiemedlemmer? Dersom de svarer at de 
ikke har noen familie; spør mer spesifikt om barn, nevøer etc. Alle har en 
familie – det kan hende at du må ut i slektsleddene. 
Ekteskap  Hva synes du om ekteskapet ditt? Hvordan er relasjonen til … (navn på 
vedkommende)? Dersom deltager er singel, enke/enkemann eller skilt, spør 
man om relasjonen til den personen de har det nærmeste relasjonen til, 
enten familie eller venn. Dersom det er en person som gir omsorg i 
hverdagen spør man om forholdet til denne.  
Venner Hvordan er forholdet ditt til vennene dine? Vil du si det er dårlig, noenlunde, godt 
eller svært godt? Hvis de svarer at de ikke har venner, eller at alle vennene 
er døde, graver du videre. Har du noen du liker å være sammen med utenom 
familien din? Vil du si at den personen er en venn? Hvis de ikke har noen i det 
hele tatt, spør: Hvordan føler du omkring det at du ikke har noen venner? 
Seg selv  Hva synes du om deg selv, med alle de sidene av deg som utgjør deg? 
Huslige gjøremål  Hvordan vil du si at dine muligheter til ting du skal gjøre i huset eller andre ting 
du trenger å få gjort? Spør om konkrete, praktiske gjøremål de må gjøre i 
hverdagen.  
Fornøyelser Hvordan er mulighetene dine for å gjøre noe gøy?  
Økonomi  Hvordan er din finansielle situasjon/økonomi? Dersom deltageren nøler, 
forklar at du ikke er interessert i pengene, men hvilke følelser/holdninger 
de selv har. 
Livet som helhet Hvordan vil du beskrive livet ditt som helhet? 
Kommentar Dersom deltager ikke klarer å svare på et av emnene kan det noteres her. 
Feltet kan også brukes dersom det er særlige forhold som virker inn på 
vurderingen ved nåværende tidspunkt. Eksempler: nylig mistet førerkort, 




Spørreskjema om helse (EQ-5D-5L) 
Under hver kategori skal deltageren krysse av «DEN ENE boksen som best beskriver helsen 
din I DAG». Det spiller ingen rolle om dagen i dag er usedvanlig god eller dårlig.  
For vurdering av «DEN SAMLEDE HELSEN I DAG» brukes VAS skala. Be deltageren peke 
på skalaen på den verdien som angir helsen i dag. Skalaen spenner fra 0 – den dårligste 
helsen deltageren kan tenke seg til 100 – den beste helsen deltageren kan tenke seg. Punktet 
som markeres av deltageren skrives inn i rubrikken i spørreskjemaet. Når dette gjøres 
elektronisk vises det laminerte spørreskjemaet til deltageren.  
Dersom deltageren ikke vil/ikke klarer å svare skal ikke svar noteres. Feltene står da blanke.  
Livskvalitet – pårørende vurderer på vegne av personen med demens (QOL-
AD proxy) 
Åpne med å si «Jeg vil nå stille deg noen spørsmål om hvordan du forstår livskvaliteten til 
den du er pårørende for/navn/relasjon, og jeg vil at du skal svare med en av følgende ord: 
dårlig, noenlunde, god eller svært god». Pek på ordene i skjemaet mens du sier alternativene. 
Bruk gjerne ordlyden: «Hva synes du om ……? Synes du det er dårlig, noenlunde, god eller 
svært god?» Tips: Gi gjerne papirversjonen til deltageren og notér selv på elektronisk. 
Dersom to eller flere delspørsmål ikke kan besvares av deltageren kan man avbryte dette 
spørreskjemaet og notere årsaken i kommentarfeltet. Se tidligere forklaring av 
enkeltspørsmålene under QOL-AD.  
Nevropsykiatriske symptom (NPI-Q modifisert) 
Dette spørreskjemaet kan fylles inn av den som spørres på vegne av personen med demens, 
men kan også gjøres i intervjuform. Spørsmålene baseres på forandringer som har 
forekommet etter at pasienten har begynt å få sviktende hukommelse. Vurder tilstanden de 
fire siste ukene. Under hvert av de 12 punktene følger en beskrivelse av symptomet i 
spørreskjemaet. Dersom pårørende skriver inn svarene selv anbefaler vi at svarene sees over, 
slik at eventuelle misforståelser kan unngås. Følgende instruksjoner står også i det 
elektroniske spørreskjemaet:  
 
Vennligst svar på følgende spørsmål basert på forandringer som har forekommet etter at 
pasienten har begynt å få sviktende hukommelse. Svar nøye på hvert enkelt spørsmål. Kryss av 
"JA" bare hvis symptomene har vært til stede siste måned. Hvis ikke, krysse av "NEI" - gå videre 
til neste spørsmål 
For hvert spørsmål som besvares med "JA" vurder følgende: Hyppighet    
1=Av og til - sjeldnere enn en gang pr. uke, 2=Ofte - omtrent en gang pr. uke. 3=Hyppig - flere 
ganger pr. uke, men sjeldnere enn hver dag, 4=Svært hyppig - daglig eller oftere. 
Alvorlighetsgrad av symptomet (hvordan det virker inn på pasienten) 
1 = Mild (merkbar, men ikke en vesentlig forandring), 2 = Moderat (betydelig, men ikke en dramatisk 
forandring), 3 = Alvorlig (svært markert eller tydelig, en dramatisk forandring) 
 
Hvor belastende du selv opplever symptomet/atferden (hvordan det påvirker deg) 
0 = Ingen belastning, 1 = Minimal (litt belastende, men ikke vanskelig å håndtere), 2 = Mild (ikke 
særlig belastende, vanligvis lett å håndtere), 3 = Moderat (ganske belastende, ikke alltid lett å 
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håndtere), 4 = Alvorlig (veldig belastende, vanskelig å håndtere), 5 = Svært alvorlig eller ekstremt 
(ekstremt belastende, umulig å håndtere) 
 
Tips: flere kan synes det er lettere om de har ett eksemplar av spørreskjemaet i papirform foran seg. 
 
Cohen Mansfield Agitation Inventory (CMAI)  
Mål: Pårørende vurderer om ulike uttrykksformer for agitasjon har forekommet hos 
personen med demens de to siste ukene. Frekvens og intensitet vurderes. Om pårørende 
svarer «Vet ikke» tolkes svaret som «aldri», dersom man etter forklaring av symptomet ikke 
klarer å huske om det forekom over de siste to ukene. Dersom det forekommer med variable 
mellomrom, forsøk å gi en vurdering etter beste evne. 
 
Bør fylles ut av pårørende direkte om mulig eller leses opp av kartleggeren. Forklar 
pårørende at det er et kartleggingsverktøy, og ikke en negativ vurdering. Ikke aksepter 
bortforklaringer av symptomer; her er det frekvensen vi er interessert i. Presiser at det er en 
kartlegging, og at forholdene ikke skal bortforklare eller rettferdiggjøres.  
 
 «Jeg skal nevne ulike handlinger eller oppførsler. Noen vil gjelde for NN og noen vil ikke 
gjøre det. Noen av disse vil lyde som negativ eller dårlig form for oppførsel, men jeg vil at du 
svarer ærlig og ikke bortforklarer dette. Vi er interessert i om det forekommer, ikke om NN 
er god eller slem. Jeg skal lese de ulike handlingene, og du anslår hvor ofte det har 
forekommet i gjennomsnitt over de siste to ukene. Dersom det ikke er mulig å vurdere sier 
du fra. Spørsmål før vi starter?» Dersom en handling forekommer med varierende 
mellomrom, gjøres en gjennomsnittsvurdering hva gjelder frekvens. Tips: flere kan synes det er 
lettere om de har ett eksemplar av spørreskjemaet i papirform foran seg.  
 
Hyppighet vurderes:  
1 Aldri  
2 Forekommer, men sjeldnere enn en gang i 
uka  
3 En eller to ganger i uka  
4 Flere ganger i uka  
5 En eller to ganger om dagen  
6 Flere ganger om dagen  
7 Flere ganger i timen 
8  Forhindres, og derfor forekommer det 
ikke 
 
Cornell – skala for depresjon (CSDD) 
Gjøres som intervju. «Jeg vil nå spørre deg som hvordan personen med demens har følt seg 
den siste uken. Jeg er interessert i endringene du har sett og hvor lenge dette har vart». NN = 
personen med demens. Alle spørsmålene besvares fra  
a.  Lar seg ikke besvare – 0 Ikke til stede – 1 Moderat eller bare periodevis til stede – 2 Mye til 
stede  
 
A) Stemningsforstyrrelser:  
1. ANGST, ENGSTELIG UTTRYKK, GRUBLING, BEKYMRING: Har NN vært 
engstelig den siste uken? Grubler han/hun over ting han/hun ikke vanligvis 
bekymrer ham/henne eller ikke er viktig? Har han/hun hatt et engstelig, anspent, 
bekymret eller engstelig uttrykk? 
2. TRISTHET, TRIST UTTRYKK, TRIST STEMME, TAR TIL TÅRENE: Har NN 
13 
 
fremstått trist eller nedfor denne uken? Har han/hun grått? Hvor mange dager 
har han/hun følt det slik? Hvor lenge hver dag? 
3. MANGLENDE EVNE TIL Å GLEDE SEG OVER HYGGELIGE HENDELSER: 
Hvis noe hyggelig hadde skjedd i dag, ville NN nyte det fullt ut eller kommer 
hans/hennes humør i veien for interessen i hendelsen/aktiviteten?  
4. IRRITABILITET, LETT IRRITERT: Har NN følt seg kortvarig eller lett irritert 
denne uken? Har han / hun følt seg irritabel, utålmodig eller sint denne uka? 
B) Forstyrret adferd:  
5. AGITERT, RASTLØS, VRIR HGENDENDE, RIVER SEG I HÅRET: Har det vært 
vanskelig for NN å sitte i ro mer enn en time grunnet rastløshet? Har du eller 
andre lagt merke til at NN er agitert? Eksempler på agitert adferd: vri hendene, 
dra seg i håret, bite seg i leppen. Er slik adferd observert i løpet av den siste uken? 
6. RETARDASJON, LANGSOMME BEVEGELSER, LANGSOM TIALE, REAGERER 
SENT: Har NN snakket saktere enn vanlig siste uken? Gjelder også saktere tanke, 
sen respons ved spørsmål og saktere motorisk aktivitet. 
7. UTTALTE KROPPSLIGE PLAGER (Skår «ikke til stede» hvis bare mage/tarm-
symptomer): Gjelder utover det som er «vanlig» for NN. Hvis det har forekommet, 
hvor plagsomt har det vært for vedkommende og hvor ofte har de forekommet? 
8. TAP AV INTERRESSE, MINDRE OPPTATT AV VANLIGE AKTIVITETER (Skår 
«moderat/periodevis til stede» eller «mye til stede» bare hvis endringen skjedde 
raskt, det vil si løpet av en måned, ellers «ikke til stede»). Har NN utvist mindre 
interesse for ting som vanligvis interesserer den siste uken? Har NN brukt mindre 
tid på disse? 
C) Kroppslige uttrykk 
9. REDUSERT APPETITT, SPISER MINDRE ENN ELLERS: Hvordan har appetitten 
over den siste uken vært sammenlignet normalt? Har NN følt seg mindre sulten 
eller måttet minne seg på å spise? Skåres «moderat/periodevis til stede» dersom det er 
appetittap, mens fremdeles NN spiser som normalt. Skåres «mye til stede» dersom NN 
bare spiser ved oppmuntring eller påminning.  
10. VEKTTAP: Har NN tapt vekt den siste måneden? Ved usikkerhet: er klærne 
løsere nå enn tidligere? Skåres «mye til stede» dersom større enn 2 kg over den 
siste måneden.  
11. TAP AV ENERGI, BLIR FORT TRETT, KLARER IKKE HOLDE UT I 
AKTIVITETER: Hvordan har energinivået vært den siste uken sammenlignet 
tidligere? Er NN trøttere hele tiden? Har NN hatt behov for blunder grunnet 
utmattethet? Har NN hatt en av følgende siste uken (som ikke skyldes kroppslige 
kjente plager): tyngdefornemmelser i lemmer, hodet eller ryggen eller følt at NN 
har dratt seg gjennom dagen? Dersom energitapet har vart i mer enn en måned uten 
forverring rates «ikke til stede» 
D) Døgnvariasjoner Æ Hva om pårørende ikke kan svare? 
12. DØGNVARIASJONER I HUMØR, VERST OM MORGENEN: Spør om NNs 
humør endrer seg gjennom dagen. Dersom ja, er det verst om morgenen? Skåres 
bare dersom symptomene er verre om morgenen. Forverring om kvelden skal ikke skåres.  
13. INNSOVNINGSVANSKER, SOVNER SENERE ENN DET SOM ER VANLIG FOR 
PASIENTEN: Har NN hatt vansker med å falle i søvn den siste uken? Hvor lenge 
er NN våken (mer enn 30 min)? Skåres «moderat/periodevis til stede» dersom det bare 
gjelder et par dager i uken, skåres «mye til stede» dersom det gjelder nesten hver eneste 
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natt.   
14. HYPPIGE OPPVÅKNINGER I LØPET AV NATTEN: Regnes ikke med dersom 
NN står opp for deretter å legge seg igjen og falle i søvn umiddelbart. Skåres 
«moderat/periodevis til stede» dersom søvnen har blitt forstyrret få ganger den siste uken, 
og NN ikke har gått ut av sengen (utenom badet). Skåres «mye til stede» dersom det 
forekommer hver natt eller andre grunner til å stå opp om natten.  
15. TIDLIG MORGENOPPVÅKNING, TIDLIGERE ENN VANLIG FOR DENNE 
PASIENTEN: Skåres «moderat/periodevis til stede» dersom NN våkner av seg selv men 
faller i søvn. Skåres «mye til stede» dersom NN våkner tidligere enn vanligere for så å stå 
opp eller ikke klarer å falle i søvn.  
E) Tankeforstyrrelser 
16. SELVMORD, FØLER LIVET IKKE ER VERDT Å LEVE, HAR 
SELVMORDSTANKER OG/ELLER GJØR SELVMORDSFORSØK: Spør gjerne om 
NN har hatt tanker om at livet ikke er verdt å leve eller at det hadde vært bedre 
om NN ikke hadde vært i live. Har NN hatt tanker om selvskading eller 
selvmord? Skåres «moderat/periodevis til stede» dersom tanker om bedre å være død, 
skåres «mye til stede» ved selvmordsønske, -planer eller –tanker. Tidligere 
selvmordstanker/-planer/-forsøk telles ikke med.  
17. DÅRLIG SEVBILDE, SELVBEBREIDELSE, SELVNEDVURDERING, 
SKYLDFØLELSE: Hvordan har NN tenkt om seg selv den siste uken? Har NN 
uttrykt spesielt selvkritiske tanker, at NN har skuffet andre, uttalt skyldfølelse 
eller at NN ikke er «god nok» eller «underlegen»? Skåres «moderat/periodevis til 
stede» ved for tap av selvfølelse. Skåres «mye til stede» ved uttrykk som «verdiløs», 
«underlegen» eller «ikke god nok».   
18. PESSIMISME, SER MØRKT PÅ FREMTIDEN: Har NN uttrykt at NN ser 
pessimistisk/mørkt på fremtiden? Har NN uttrykt at fremtiden er håpløs? 
Beroliges NN ved positive innspill? Skåres «moderat/periodevis til stede» dersom 
pessimisme uttrykkes, men at dette kan reduseres ved innspill. Skåres «mye til stede» 
dersom håpløshet uttrykkes eller NN ikke beroliges av positive innspill.  
19. VRANGFORESTILLINGER SOM SAMSVARER MED Å VÆRE DEPRIMERT: 
Uttrykker NN at sykdom er en straff eller påført av andre? At NN selv påfører 
andre sykdom og ev død? At kriger, terror, naturkatastrofer kunne vært unngått 
dersom NN var død?   
 
I-ADL og P-ADL  
Utgangspunktet for avkrysning er hva pasienten faktisk utfører i hverdagen og ikke hva 
han/hun kan klare eller er i stand til å mestre fysisk sett. 0 skåres bare dersom det ikke er 
aktuelt. Eks: Dersom vedkommende ikke bruker medisiner skåres det «ikke aktuelt» på dette 
feltet.  
 
PADL er de personnære aktivitetene i dagliglivet, som hygiene, spising og mobilitet.  






Det ene nivået som best passer til pasientens funksjonsnivå skal velges. Obligatorisk. 
FAST-vurdering Beskrivelse 
1 Ingen vanskeligheter med hukommelsen, verken subjektivt eller objektivt Normal funksjon til mild 




2 Klager over å ha forlagt ting. Opplever selv vanskeligheter 
med å utføre arbeidsoppgaver. 
3 
Redusert arbeidsfunksjon, åpenbart for kolleger. 
Vanskeligheter med å reise til nye steder ved egen hjelp. 
Reduserte evner til å organisere arbeid og andre oppgaver. 
4 
Redusert evne til å utføre sammensatte oppgaver, ivareta 
privat økonomi (glemmer å betale regninger)  som å 
arrangere middagsselskap etc. 
Moderat kognitiv 
nedsettelse 
5 Behøver assistanse for å kle seg adekvat for anledningen, i det daglige eller ved spesielle anledninger/høytider. 
Moderat til alvorlig 
kognitiv nedsettelse: På 
dette tidspunkt kreves noe 
assistanse i dagliglivet. 
6 
a) Behøver assistanse til å kle seg ordentlig (glemmer å 
ta av pysjamasen først, tar skoene på feil fot, greier 
ikke å kneppe knapper etc).  
b) Kan ikke bade selv (vansker med å finne riktig 
temperatur på badevannet etc). Av og til eller oftere 
de siste ukene.  
c) Kan ikke gjennomføre toalettbesøk alene (glemmer 
å trekke i snoren, tørke seg ordentlig, glemmer å 
kaste toalettpapir etc.). Av og til eller oftere de siste 
ukene.  
d) Inkontinent for urin. Av og til eller oftere de siste 
ukene.  
e) Inkontinent for avføring. Av og til eller oftere de 
siste ukene. 
Alvorlig kognitiv 
nedsettelse: I denne fasen 
vil man gradvis kreve mer 
og mer assistanse for å 
ivareta hygiene. 
7 
a) Ordforrådet er begrenset til 6-10 forskjellige ord, 
som brukes i løpet av en vanlig dag eller de 
kommer frem under samtale/grundig intervju.  
b) Ordforrådet er begrenset til et enkelt ord.  
c) Redusert evne til å bevege seg rundt. Må ha hjelp til 
å gå. 
d) Er ikke i stand til å sitte oppreist uten støtte fra 
stolens armlener. 
e) Har mistet evnen til å smile.  
f) Kan ikke løfte hodet ved egen hjelp. 
Ordforråd og mulighet til 
interaksjon med 
omgivelsene avtar. 
Eksempel: Personen med demens er operert for prostatabesvær og har blitt inkontinent for 
urin som følge av dette. Han har klarer dagligdagse gjøremål, inkludert påkledning, men 
strever med mer komplekse arbeidsoppgaver.  Derfor skal han rates med 4 og ikke 6D (siden 




Spørreskjema til pårørende (IQCODE) 
Spørreskjemaet avdekker endringene hos personen med demens over de siste 10 årene. Kan 
fylles inn direkte av pårørende selvstendig.  
 
«Når du besvarer spørsmålene, tenk på hvordan din slektning eller venn var for ti år siden 
og sammenlign med situasjonen i dag. Nedenfor er det angitt noen situasjoner hvor 
vedkommende må bruke sitt intellekt. Vurder om dette har blitt bedre, er uforandret eller 
blitt forverret i løpet av de siste ti årene. Hvis din slektning eller venn ikke husket hvor 
han/hun la fra seg ting for ti år siden og det samme er tilfellet i dag, skal det besvares med 
ikke særlig forandret».  
 
Svaralternativene varierer fra: Mye bedre – Litt bedre – Ikke særlig forandre – Litt verre – 
Mye verre. Pårørende skal bare angi ett svar pr delspørsmål. Hva gjelder symptomstart 
velges antall år tilbake, ikke årstall.  
 
Geriatrisk depresjonsskala (GDS) 
Selvevalueringsskala som avdekker depresjon hos eldre den siste uken. Brukes i denne studien 
på alle pårørende. Pårørende kan fylle ut denne selv eller gjennomføres som intervju. Alle de 
30 spørsmålene skal besvares med ja/nei.  
Belastningsskala for pårørende (RSS) 
Et verktøy for å vurdere hvorvidt pasientens pårørende føler seg belastet av å være 
omsorgsgiver til en person som lider av demens. 
Svaralternativene varierer fra: 0 Aldri/ingen – 1 sjelden/litt – 2 av og til/moderat – 3 
ofte/ganske mye – 4 alltid/svært mye   
Tips: 
IQCODE, GDS og belastningsskala for pårørende kan alle besvares ved selvrapportering. 
Om pårørende er sliten eller vil gjennomføre en annen dag, kan vedkommende besvare disse 
siste spørreskjemaene på papir. Han/hun kan deretter levere det inn til kartlegger etter 






Egne notater  
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Har du husket å ta med deg dette på 
kartlegging? 
 
- Informasjonsbrosjyre (papirform) 
- Denne manualen (papirform) 
- To nettbrett for elektronisk registrering (ett til PMD og ett til pårørende)  
- Spørreskjema-pakken i papirutgave (minst ett eksemplar til både PMD og 
pårørende, samt koordinator) i tilfelle tekniske problemer med nettbrett 
- Laminert VAS 
- MMSE i papirform 
- Vekt 
- Blodtrykksapparat  
 
Tips for datainnsamling 
- Vi anbefaler at to personer innhenter baselinedata, da samtykke og informasjon skal 
innhentes fra både PMD og pårørende, samt en ny situasjonen for deltagerne.  
- Ved utfylling av PMDs spørreskjema anbefaler vi at pårørende er tilstede til og med 
utfyllingen av Helseøkonomisk spørreskjema (RUD), og etter skjønn på 
velferdsteknologi og frivillighet.  
- En pragmatisk holdning til lokalisasjon kreves og smidighet må utvises for inklusjon 
av pasienter 
- Dersom det avdekkes at deltagerne ikke får forsvarlig helsehjelp er det viktig at 
slike situasjoner håndteres etter gjeldende retningslinjer og lovverk som i 
helsetjenesten for øvrig.  
- MMSE gjennomføres i papirform og de øvrig baselinekartlegging gjøres elektronisk på 
nettbrett. Sub- og totalscore MMSE fylles inn elektronisk, mens originalversjonen 









Dato for kartlegging: 
ID-KODE personen med demens (PMD):  
 
LIVE@HOME.PATH     Baseline kartlegging 
Innhold: 
Bakgrunnsopplysninger. Til stede ved utfylling: PMD, pårørende 
Sykdomsanamnese. Til stede ved utfylling: PMD, pårørende 
Helseøkonomisk spørreskjema (RUD). Til stede ved utfylling: PMD, pårørende 
Kartlegging av helseteknologi og frivillighet. Til stede: PMD (og pårørende, hvis nødvendig) 
Minimental Status Evaluation (MMSE). Til stede: PMD 
Fysiske observasjoner. Til stede: PMD 
Smerteskala: MOBID-2. Til stede: PMD 
Vurdering av egen livskvalitet (QOL-AD). Til stede: PMD 
Spørreskjema om helse (EQ-5D-5L). Til stede: PMD 
 
General Medical Health Rating (GHMR). Til stede: PMD 















1) Fødselsdato: ______________________ 
2) Demenstype:       ⎕ Alzheimers sykdom  ⎕ Vaskulær demens  ⎕ Lewy-legeme demens  
⎕ Demens ved andre sykdommer klassifisert annet steds (Parkinsons sykdom, Huntingtons 
sykdom, CJD, Picks syndrom, infeksjonssykdommer osv.) 
⎕ Frontallappsdemens  ⎕Blandet/uspesifisert demens  
3) Kjønn: Kvinne ⎕     Mann ⎕  
4) Diagnosetidspunkt (år): ________________________ 
5) Har det forekommet en/flere uheldige hendelse(r) i løpet av de siste 6 månedene (f. eks 
fall, brann, at personen med demens har gått seg vill, vold etc.)? 
⎕ Nei       ⎕ Ja  
Dersom ja, kan du spesifisere/beskrive  
⎕Personen med demens har gått seg vill   ⎕Fall    ⎕ Brann    
⎕ Vold (lugging, biting, slåing etc.)     ⎕ Annet, spesifiser _____________________ 
 
6) Har du i løpet av de siste seks månedene diskutert medisinene du bruker med din fastlege?  















Sykdomsanamnese Har noen av følgende tilstander vært diagnostisert (ifølge opplysninger fra 
pasient og/eller pårørende)? Hvis ja på spørsmålene under, angi type. Flere kryss er tillatt.  




⎕ Forbigående lammelser/språkforstyrrelser 
⎕ Annen cerebrovaskulær sykdom 
Er det mindre enn 3 måneder mellom hjerneslag/TIA og debut av mental svikt? ⎕ Ja  ⎕ Nei 
Annen sykdom eller skade i sentralnervesystemet?                                  ⎕ Ja           ⎕ Nei 
⎕ Parkinsonisme/Parkinsons sykdom 
⎕ Epilepsi 
⎕ Tidligere hodetraume med bevisstløshet 
⎕ Encefalitt/meningitt 
⎕ Infeksjon som kan gi cerebral affeksjon (Borrelia, TBC, HIV, Lues) 
⎕ Annen nevrologisk lidelse av betydning for aktuell tilstand 
Kardiovaskulær sykdom?                                                                                  ⎕ Ja           ⎕Nei 
⎕ Høyt blodtrykk 
⎕ Atrieflimmer 
⎕ Hjertesvikt 
⎕ Angina pectoris 
⎕ Hjerteinfarkt 
⎕ Annen hjerte sykdom 
⎕ Hjerteoperasjon før hukommelsesproblemene oppsto 










Psykisk lidelse                                                                                                   ⎕   Ja            ⎕  Nei  
⎕ Nåværende depresjon 
⎕ Tidligere depresjon 
⎕ Angstlidelse 
⎕ Psykoselidelse 
⎕ Bipolar lidelse 
⎕ Annen nåværende psykisk lidelse 
⎕ Annen tidligere psykisk lidelse 
Andre sykdommer av betydning for aktuell tilstand?                                ⎕ Ja                  ⎕ Nei 
⎕ Kreftsykdom 
⎕ Kronisk obstruktiv lungesykdom 
⎕ Leddgikt 
⎕ Kronisk nyresykdom 
⎕ Annen sykdom 
Smerterelaterte plager                                                                              ⎕ Ja                  ⎕ Nei 
⎕ Muskel og skjelettplager                                                             ⎕ Kontrakturer 
⎕ Gammelt brudd                                                                           ⎕ Artritt 
⎕ Hodepine                                                                                      ⎕ Osteoporose 
⎕ Gyn/urologisk smerte 
⎕ Nevropati i forbindelse med diabetes, slag, herpes zoster +++ 
⎕ Magesmerter 
⎕ Tannpine eller smerte i munnen 
⎕ Kreftrelaterte smerter 
⎕ Hud/sår/gangren 









Helseøkonomisk spørreskjema (RUD) 
1. Vennligst angi pasientens nåværende boform. 
 
1.  Egen bolig (selveid eller leid)   
2.  Omsorgsbolig (ikke demenstilpasset)     
3.  Demenstilpasset botilbud       
4.  Annet   
 
2. Hvem bor pasienten sammen med? 
 
1.  Alene  
2.  Ektefelle  
3.  Søsken  
4.  Barn  
5.  Andre  
6.  Ikke aktuelt  
 
3.  Dersom det i løpet av de siste 30 dager har skjedd en midlertidig endring i pasientens 
boform (f.eks. flyttet til annet sted i mer enn 24 timer og så tilbake til opprinnelig bosted), 
vennligst angi antall overnattinger tilbrakt i denne midlertidige boformen.  
 
 
 Antall overnattinger 
1. Egen bolig (eiet eller leid) ___ 
2. Omsorgsbolig (ikke demenstilpasset) ___ 
3. Demenstilpasset botilbud  ___ 
4. Langtidsplass på institusjon (for eksempel sykehjem) ___ 






A2.2 Pasientens bruk av helsetjenester 
 
1. Hvor mange ganger har pasienten vært innlagt på sykehus (i mer enn 24 timer) i 
løpet av de siste 30 dager? 
     Ingen 
  
2. Hvis pasienten har vært innlagt på sykehus de siste 30 dager, vennligst angi antall 
døgn på hver type avdeling. 
 






Annet (vennligst spesifiser)  
 
3.  Hvor mange ganger har pasienten vært til akuttbehandling på sykehus (i mindre enn 
24 timer) i løpet av de siste 30 dager? 
    Ingen 
 
4. De siste 30 dager, hvor mange ganger har pasienten oppsøkt lege, fysioterapeut, 
psykolog eller annet helsepersonell. Vennligst angi antall besøk for hver type tjeneste.  




   Antall ganger 




















5. For hver av tjenestene nedenfor, vennligst angi antall ganger tjenestene ble mottatt 
de siste 30 dager og gjennomsnittlig antall timer per besøk.  
 Pasienten har ikke mottatt slike tjenester i løpet av de siste 30 dager. 
 
Tjeneste Antall besøk de siste 30 dager Antall timer per besøk 
Hjemmesykepleier   
Hjemmehjelp/hjelpepleier   
Matombringning  N/A 
Dagsenter   
Transport (omsorg/helserelatert)  N/A 









6. Vennligst oppgi hvilke medisiner du bruker for tiden (reseptbelagte og reseptfrie). 
 Jeg bruker ingen medisiner for tiden  
 
Skriv inn: medikamentnavn, styrke, administrasjonsform og antall daglig doseringer (merk ved behov 


















Har du i dag helseteknologi?    Ja ⎕   Nei ⎕ 
Dersom ja, vennligst kryss av om du har en/flere av følgende: 
Trygghetsalarm ⎕     Fallsensor ⎕     Dørkamera ⎕   Komfyrvakt ⎕    
Trygghetsalarm med GPS ⎕     Medisindispenser (f.eks. Pilly) ⎕    
Klokke med påminnefunksjon/tale ⎕    Kalenderstøtte til å organisere hverdagen ⎕ 
Sengematte/sensorlaken ⎕      Tidsbryter til elektriske apparat ⎕       
Elektronisk dørlås ⎕     Vannsensor på bad/kjøkken ⎕         Kjøleskapssensor ⎕ 
Videokommunikasjon med pårørende/venner (Komp) ⎕      





Dersom du har velferdsteknologi som brukes sjelden eller ikke i det hele tatt, hva skyldes 
dette? 
Passer ikke mitt behov   ⎕ 
Ikke tilpasset behov ⎕ 
Manglende opplæring   ⎕ 
Føler meg overvåket    ⎕ 
Er mer plage enn til nytte ⎕ 










1. Har du en frivillig (f. eks. aktivitetsvenn, besøksvenn eller lignende fra organisert 
tjeneste eller organisasjon) du tilbringer tid med?        
 
⎕ JA, dersom ja gå videre til spørsmål 2.       ⎕NEI, dersom nei gå videre til spørsmål 6.  
 
2. Hvis ja; hvor lenge har dere hatt kontakt? ⎕ Mindre enn 3 mnd.  ⎕ 3-6 mnd. ⎕ 6-12 
mnd.  
                                                                                         ⎕13-24 mnd.                ⎕ Mer enn 2 år  
3.  Hva synes du om hyppigheten på møtene?  
          ⎕ Burde treffes oftere          ⎕ Er tilfreds med dagens ordning      ⎕ Burde treffes 
 sjeldnere  
4.  Hva syns du om lengden på møtene?  
 
⎕ Er for kort                         ⎕ Er passelig                                        ⎕ Varer for lenge 
 





6. Hvis nei: ønsker du kontakt med en frivillig? ⎕ Ja ⎕ Nei  
 
7.  Hvi nei; Hvorfor ønsker du ikke kontakt med en frivillig?   
           ⎕ Har ikke tenkt på muligheten  
           ⎕ Ønsker ikke hjelp/besøk av fremmede  
           ⎕ Ønsker heller å betale for tjenester  
           ⎕ Annen grunn, spesifiser   _____________________________________________ 
8. Hvilken aktiviteter ønsker du å gjøre sammen med den frivillige? 
          ⎕ Sport/natur  ⎕ Kultur/underholdning ⎕ Håndverk/forming   






Mini Mental Status Evaluation 
 
Orientering: _____________________ (x/10) 
Umiddelbar gjenkalling: _________________________ (x/3) 
Hoderegning: _________________________________ (x/5) 
Utsatt gjenkalling: ______________________________ (x/3) 
Språk og praksis: _______________________________ (x/8) 
Figurkopiering: _________________________________ (x/1) 




Følgende målinger foretas av personen med demens hver 6. mnd. som del av studien. 
Vekt (kg): ____________   
Høyde (cm): ____________     
Puls (slag/min): ____________  
Systolisk blodtrykk: __________________  

















Vurdering av egen livskvalitet (QOL-AD). Sett et kryss ved intervjupersonens svar. 
 
1. Fysisk helse Dårlig Noenlunde God Svært god 
2. Arbeidslyst Dårlig Noenlunde God Svært god 
3. Sinnsstemning Dårlig Noenlunde God Svært god 
4. Bosituasjon Dårlig Noenlunde God Svært god 
5. Hukommelse Dårlig Noenlunde God Svært god 
6. Familie Dårlig Noenlunde God Svært god 
7. Ekteskap Dårlig Noenlunde God Svært god 
8. Venner Dårlig Noenlunde God Svært god 
9. Seg selv Dårlig Noenlunde God Svært god 
10.  Huslige gjøremål Dårlig Noenlunde God Svært god 
11. Fornøyelser Dårlig Noenlunde God Svært god 
12. Økonomi Dårlig Noenlunde God Svært god 



































Spørsmål om daglig aktivitet 
















Er du fornøyd med det aktivitetsnivået du har nå?   Ja ⎕    Nei ⎕ 
 
Er det noen aktiviteter du har sluttet med i løpet av den siste måned?   Ja ⎕ Nei ⎕ 
 
Hva anser du som den viktigste årsaken til dette?  
Mistet interesse ⎕     Føler meg ikke i stand til å utføre aktiviteten ⎕   
Dårlig fysisk helse ⎕      








Dato for kartlegging: 
ID-KODE pårørende:  
 
 
LIVE@HOME.PATH     Baseline kartlegging 
Innhold: 
Til stede: pårørende 
Helseøkonomisk spørreskjema (RUD). 
Spørreskjema for livskvalitet (QoAL-AD) – pårørende svarer på vegne av seg selv. 
Spørreskjema om helse (EQ-5D-5L) – pårørende svarer på vegne av seg selv. 
Spørreskjema om livskvalitet - pårørende svarer på vegne av personen med demens (QoAL-
AD- proxy). 
Neuropsychiatric Inventory (NPI) 
Agitasjonsskala (CMAI)   
Skala for depresjon (CSDD) – pårørende svarer på vegne av personen med demens. 
Aktiviteter i dagliglivet (I-ADL og P-ADL). 
Functional Assessment Staging (FAST) 
Følgende spørreskjemaene kan pårørende evt. fylle ut på papir og kan hentes av koordinator 
ila neste to dager:  
Spørreskjema til pårørende (IQCODE) 
Geriatrisk depresjonsskala (GDS) - Pårørende svarer på vegne av seg selv! 





Helseøkonomisk spørreskjema (RUD) 
A1. OMSORGSGIVER 
A1.1 Beskrivelse av hoved omsorgsgiver 
1 Fødselsdato: ______________ 
2. Kjønn: 
1.  Mann   
2.  Kvinne   
3. Forhold til pasient: 
1.  Ektefelle  
2.  Søsken  
3.  Barn  
4.  Venn  
5.  Annet     
4. Antall barn som bor sammen med deg: ______ barn 
5. Bor du sammen med pasienten? 
1.  Ja  
2.  Nei  
6. Hvor mange andre omsorgsgivere er involvert i omsorgen? 
 0   
 1   
 2   
 3   







7. Av alle omsorgsgiverne, hvor mye bidrar du? 
 1. 1-20%   
 2. 21-40%   
 3. 41-60%   
 4. 61-80%   
 5. 81-100%   
8. Har du deltatt på pårørendekurs?    Ja ⎕       Nei ⎕ 
Omsorgsgivers tidsbruk 
1. På en typisk omsorgsdag de siste 30 dager, hvor mye sov du i løpet av døgnet? 
 
    timer og   minutter per dag og natt 
 
2a). På en typisk omsorgsdag de siste 30 dager, hvor mye tid per dag brukte du på å hjelpe 
pasienten med oppgaver som toalettbesøk, måltider, påkledning, stell, forflytning og 
bading?  
 
   timer og    minutter per dag  
 
2b). I løpet av de siste 30 dager, hvor mange dager brukte du på å hjelpe pasienten med 
slike gjøremål?  
 
    dager     
 
3a). På en typisk omsorgsdag de siste 30 dager, hvor mye tid per dag brukte du på å hjelpe 
pasienten med oppgaver som innkjøp, matlaging, husarbeid, klesvask, transport, 
medisinering og håndtering av økonomi? 
 
    timer og   minutter per dag 
 
    
 




    dager     
 
4a). På en typisk omsorgsdag de siste 30 dager, hvor mye tid per dag brukte du på å ha 
tilsyn med pasienten (for eksempel for å forhindre farlige hendelser)? 
 
    timer og   minutter per dag 
 
4b). I løpet av de siste 30 dager, hvor mange dager brukte du på slikt tilsyn?  
    dager      
 
A1.3 Omsorgsgivers arbeidsforhold 
Vennligst velg utdanningsnivå:  
 Grunnskolenivå      Videregående nivå     Universitet/høyskole til og med 4 år  
  Universitet/høyskole mer enn 4 år      Fagutdannelse (fagbrev, yrkesskole) 
Yrke: ___________________________________ 
Ansiennitet: ______________________________ 
1. Har du for tiden inntektsgivende arbeid? 
1.  Ja  Hvis ja, besvar spørsmål 3 til 5 
2.  Nei  Hvis nei, besvar kun spørsmål 2 
2. Hvorfor sluttet du/reduserte du arbeidstiden? 
1.  Har aldri vært i arbeid  
2.  Nådde pensjonsalder  
3.  Førtidspensjonert  
(ikke sykdomsrelatert) 
4.  Ble oppsagt  
5.  Egne helseproblemer  
6.  For å gi omsorg til pasienten  
7.  Annet   




    Ingen 
 
4. Av dette timeantallet, hvor mange timer per uke lønnes du for å ta deg av pasienten 
(omsorgslønn)?  
    Ingen 
 
5. I løpet av de siste 30 dager, hvor mange timer per uke har du måttet redusere din ordinære 
arbeidstid på grunn av omsorgsansvar for pasienten?  
    Ingen 
 
6. I løpet av de siste 30 dager, vennligst angi antall ganger omsorgsansvaret har påvirket 
arbeidet ditt på følgende måter: 
A.  Gått glipp av en hel arbeidsdag 
    Ingen 
 
B.  Gått glipp av deler av en arbeidsdag  
    Ingen 
 
A1.4 Omsorgsgivers bruk av helsetjenester 
 
1. Hvor mange ganger har du vært innlagt på sykehus (i mer enn 24 timer) i løpet av de siste 
30 dagene? 
 
    Ingen 
  
  
   Timer per uke 
   Timer per uke 
   Timer per uke 
   Antall ganger 
   Antall ganger 




2. Hvis du har vært innlagt på sykehus i løpet av de siste 30 dager, vennligst angi totalt hvor 
mange døgn på hver type avdeling. 
 






Annet (vennligst spesifiser)  
 
 
3. I løpet av de siste 30 dager, hvor mange ganger har du vært til akuttbehandling på sykehus 
(i mindre enn 24 timer)?        
  




   Antall ganger 
7 
 
4. I løpet av de siste 30 dager, hvor mange ganger har du oppsøkt lege, fysioterapeut, 
psykolog eller annet helsepersonell. Vennligst angi antall besøk for hver type helsetjeneste.  
 Jeg har ikke benyttet meg av noen slike helsetjenester de siste 30 dager. 
 













5. Vennligst oppgi hvilke medisiner du bruker for tiden (reseptbelagte og reseptfrie). 
 Jeg bruker ingen medisiner for tiden  
 
















Hvordan vurderer du, som pårørende, din egen livskvalitet? 
1.  Fysisk helse Dårlig Noenlunde God Svært god 
2. Arbeidslyst Dårlig Noenlunde God Svært god 
3.  Sinnsstemning Dårlig Noenlunde God Svært god 
4.  Bosituasjon Dårlig Noenlunde God Svært god 
5. Hukommelse Dårlig Noenlunde God Svært god 
6. Familie Dårlig Noenlunde God Svært god 
7. Ekteskap Dårlig Noenlunde God Svært god 
8.  Venner Dårlig Noenlunde God Svært god 
9.  Seg selv Dårlig Noenlunde God Svært god 
10. Huslige gjøremål Dårlig Noenlunde God Svært god 
11. Fornøyelser Dårlig Noenlunde God Svært god 
12. Økonomi Dårlig Noenlunde God Svært god 



















Livskvalitet (QoL-AD proxy) 
Hvordan vurderer du livskvaliteten til familiemedlemmet med demens? 
1.  Fysisk helse Dårlig Noenlunde God Svært god 
2. Arbeidslyst Dårlig Noenlunde God Svært god 
3.  Sinnsstemning Dårlig Noenlunde God Svært god 
4. Bosituasjon Dårlig Noenlunde God Svært god 
5. Hukommelse Dårlig Noenlunde God Svært god 
6. Familie Dårlig Noenlunde God Svært god 
7. Ekteskap Dårlig Noenlunde God Svært god 
8. Venner Dårlig Noenlunde God Svært god 
9. Seg selv Dårlig Noenlunde God Svært god 
10. Huslige gjøremål Dårlig Noenlunde God Svært god 
11. Fornøyelser Dårlig Noenlunde God Svært god 
12. Økonomi Dårlig Noenlunde God Svært god 










Neuropsychiatric Inventory (NPI-Q modifisert)  
Vennligst svar på følgende spørsmål basert på forandringer som har forekommet etter at pasienten har 
begynt å få sviktende hukommelse. Svar nøye på hvert enkelt spørsmål. Be oss om å hjelpe dersom du 
har noen spørsmål. Kryss av "JA" bare hvis symptomene har vært til stede siste måned. Hvis ikke, krysse 
av "NEI" - gå videre til neste spørsmål 
For hvert spørsmål som besvares med "JA" vurder følgende: Hyppighet    
1=Av og til - sjeldnere enn en gang pr. uke.      
2=Ofte - omtrent en gang pr. uke. 
3=Hyppig - flere ganger pr. uke, men sjeldnere enn hver dag. 
4=Svært hyppig - daglig eller oftere. 
Alvorlighetsgrad av symptomet (hvordan det virker inn på pasienten) 
1 = Mild (merkbar, men ikke en vesentlig forandring) 
2 = Moderat (betydelig, men ikke en dramatisk forandring) 
3 = Alvorlig (svært markert eller tydelig, en dramatisk forandring) 
Hvor belastende du selv opplever symptomet/atferden (hvordan det påvirker deg) 
0 = Ingen belastning 
1 = Minimal (litt belastende, men ikke vanskelig å håndtere)  
2 = Mild (ikke særlig belastende, vanligvis lett å håndtere) 
3 = Moderat (ganske belastende, ikke alltid lett å 
håndtere) 4 = Alvorlig (veldig belastende, vanskelig å 
håndtere) 
5 = Svært alvorlig eller ekstremt (ekstremt belastende, umulig å håndtere) 
1. Vrangforestillinger 
Har pasienten oppfatninger som du vet ikke er 
riktige? F. eks. tror at andre stjeler fra ham/henne 
eller at andre planlegger å skade ham/henne på en 
eller annen måte? 
Nei Ja 
Hyppighet         1-2-3-4 
Alvorlighetsgrad         1-2-3 
Belastning         0-1-2-3-4-5 
2. Hallusinasjoner 
Har pasienten hallusinasjoner slik som uvirkelige 
syner eller stemmer? Virker det som om han/hun ser 
eller hører ting som ikke er virkelige?  
Nei Ja 
 
Hyppighet     1-2-3-4 
Alvorlighetsgrad       1-2- 3 
Belastning     0-1-2-3-4-5 
3.      Agitasjon/aggresjon 
Har pasienten perioder der han/hun motsetter seg 
hjelp fra andre, eller er vanskelig å ha med å gjøre? 
Nei Ja 
 
Hyppighet     1-2-3-4 
Alvorlighetsgrad       1-2-3  
Belastning     0-1-2-3-4-5 
4.      Depresjon/dysfori 




Hyppighet      1-2-3-4 
Alvorlighetsgrad        1-2-3 




Blir pasienten nervøs /urolig når han/hun er adskilt 
fra deg? Viser han/hun andre tegn til nervøsitet slik 
som tungpustenhet, sukking, ute av stand til å 
slappe av eller føler seg svært anspent? 
Nei Ja 
 
Hyppighet     1-2-3-4 
Alvorlighetsgrad      1-2-3 
Belastning     0-1-2-3-4-5 
6     Oppstemthet/eufori 
Synes pasienten å føle seg uvanlig munter eller 
oppfører seg som om han/hun er svært lykkelig? 
Nei Ja 
 
Hyppighet  1-2-3-4 
Alvorlighetsgrad    1-2-3  
Belastning  0-1-2-3-4-5 
 
7     Apati/likegyldighet 
Virker pasienten mindre interessert i sine vanlige 
aktiviteter og i andres gjøremål og planer? 
Nei Ja 
 
Hyppighet      1-2-3-4 
Alvorlighetsgrad     1-2-3  
Belastning     0-1-2-3-4-5 
8    Manglende hemninger 
Virker det som om pasienten handler impulsivt, f.eks. 
snakker til fremmede personer som om han/hun 




Hyppighet     1-2-3-4 
Alvorlighetsgrad      1-2-3 
Belastning     0-1-2-3-4-5 
9    Irritabilitet/labilitet 
Er pasienten utålmodig og irritabel? Har han/hun 
vanskelig for å takle forsinkelser eller venting på 




Hyppighet     1-2-3-4 
Alvorlighetsgrad    1-2-3  
Belastning    0-1-2-3-4-5 
10   Avvikende motorisk atferd 
Utfører pasienten stadig gjentatte handlinger slik 
som å vandre rundt i huset, fingre med knapper, vri 




Hyppighet     1-2-3-4 
Alvorlighetsgrad    1-2-3  
Belastning    0-1-2-3-4-5 
11   Søvn 
Vekker pasienten deg i løpet av natten, våkner for 
tidlig om morgenen eller sover mye på dagtid? 
Nei Ja 
 
Hyppighet  1-2-3-4 
Alvorlighetsgrad    1-2-3  
Belastning   0-1-2-3-4-5 
12   Appetitt/spising 
Har pasienten hatt vekttap eller vektøkning? Har 
han/hun endret typen mat han/hun foretrekker? 
Nei Ja 
 
Hyppighet  1-2-3-4 
Alvorlighetsgrad    1-2-3 



























Kryss av for det nivå som samsvarer suksessivt best med pasientens 
funksjonsnivå. 
 
1) ⎕ Ingen vanskeligheter med hukommelsen, hverken subjektivt eller objektivt. 
 
2) ⎕ Klager over å ha forlagt ting. Opplever selv vanskeligheter med å utføre arbeidsoppgaver. 
 
3) ⎕ Redusert arbeidsfunksjon, åpenbart for kolleger. Vanskeligheter med å reise til nye steder ved 
egen hjelp. Redusert evne til å organisere arbeid og andre oppgaver. 
 
4) ⎕ Redusert evne til å utføre sammensatte oppgaver, ivareta privat økonomi (glemmer å betale 
regninger) som å arrangere middagsselskap etc. 
 




A. ⎕ Behøver assistanse til å kle seg ordentlig (glemmer å ta av pyjamasen først,  
tar skoene på feil fot, greier ikke å kneppe knapper etc).  
B. ⎕ Kan ikke bade selv (vansker med å finne riktig temperatur på badevannet etc).  
Av og til, eller oftere de siste ukene. 
C. ⎕ Kan ikke gjennomføre toalettbesøk alene (glemmer å trekke i snoren, tørke seg 
ordentlig, glemmer å kaste toalett papir etc.). Av og til, eller oftere de siste 
ukene. 
D. ⎕ Inkontinent for urin. Av og til, eller oftere de siste ukene.  
E. ⎕ Inkontinent for avføring. Av og til, eller oftere de siste ukene. 
 
7)  
A. ⎕ Ordforrådet er begrenset til ca. 6-10 forskjellige ord, som brukes i løpet av  
en vanlig dag eller de kommer frem under samtale/grundig intervju. 
B. ⎕ Ordforrådet er begrenset til et enkelt ord. Dette repeteres gjerne om igjen. 
C. ⎕ Redusert evne til å bevege seg rundt. Må ha hjelp til å gå.  
D. ⎕ Er ikke i stand til å sitte oppreist uten støtte fra stolens armlene.  
E. ⎕ Har mistet evnen til å smile.  








GDS Geriatrisk depresjonsskala   
Nedenfor finner du 30 spørsmål om hvordan du (som pårørende) har følt deg den siste 
uken. Vær vennlig å krysse av for det svaret som passer best for deg. 
1. Føler du deg jevnt over tilfreds med livet __________________________ □Ja □ Nei   
2. Har du oppgitt eller sluttet med mange interesser___________________ □ Ja □ Nei   
3. Føler du at livet er tomt________________________________________ □ Ja □ Nei   
4. Synes du ofte at tilværelsen er kjedelig ___________________________ □ Ja □ Nei   
5. Ser du lyst på fremtiden________________________________________ □ Ja □ Nei   
6. Er du plaget med tanker som du ikke får ut av hodet ________________ □ Ja □ Nei  
7. Er du vanligvis i godt humør ____________________________________ □ Ja □ Nei   
8. Er du engstelig for at det skal hende deg noe alvorlig ________________ □ Ja □ Nei  
 9. Føler du deg vanligvis lykkelig___________________________________ □ Ja □ Nei   
10. Føler du deg ofte hjelpeløs____________________________________ □ Ja □ Nei  
11. Føler du deg ofte urolig og rastløs ______________________________ □ Ja   □ Nei   
12. Foretrekker du å være hjemme fremfor å gå ut å oppleve nye ting ____ □ Ja □ Nei   
13. Er du bekymret for din egen fremtid____________________________ □ Ja □ Nei   
14. Føler du at du har større problem med hukommelsen enn mange andre (jevnaldrende) 
_____________________________________________________________  □ Ja   □ Nei   
15. Føler du i øyeblikket at det er godt å leve_________________________ □ Ja □ Nei  
 16. Føler du deg ofte nedtrykt og ensom____________________________ □ Ja □ Nei   
17. Føler du deg verdiløs slik du nå er_______________________________ □ Ja □ Nei   
18. Bekymrer du deg ofte over fortiden_____________________________   □ Ja   □ Nei 
19. Synes du livet er spennende__________________________________   □ Ja □ Nei   
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20. Er det et tiltak å ta fatt på noe nytt_____________________________   □ Ja □ Nei  
21. Føler du deg opplagt________________________________________ □ Ja □ Nei   
22. Synes du at din egen situasjon er håpløs________________________ □ Ja   □ Nei   
23. Synes du at folk flest har det bedre enn deg_____________________ □ Ja   □Nei   
24. Blir du ofte forstyrret av bagateller____________________________ □ Ja   □ Nei   
25. Føler du ofte trang til å gråte_________________________________ □ Ja   □ Nei   
26. Har du vansker med konsentrasjonen__________________________ □ Ja   □ Nei   
27. Liker du å stå opp om morgenen______________________________ □ Ja   □ Nei   
28. Forsøker du å unngå sosiale sammenkomster____________________ □ Ja   □ Nei   
29. Faller det deg lett å ta bestemmelser___________________________ □ Ja   □ Nei   






NORSK REVIDERT MINI MENTAL STATUS EVALUERING (MMSE–NR3)
Carsten Strobel & Knut Engedal, 2016 (oppdatert 2018)
Administrasjons- og skåringsveiledning
Screeningtesten MMSE-NR brukes til kognitiv utredning og forløpskontroll ved demens, hjerneslag og andre sykdommer som påvirker kognitiv 
funksjon, og for å vurdere behandlingseffekt,  kognitiv  egnethet for bilkjøring o.l.  Testen alene er ikke tilstrekkelig til  å  diagnostisere demens. 
Diagnose kriteriene for demens må også være  oppfylt. MMSE-NR  supplerer  annen  utredning så som somatisk under søkelse, legemiddel -
gjennomgang, komparentintervju (med bl.a. spørsmål om type/forløp/varighet av  ev.  kognitiv svikt og  endret ADL-funksjon) og vurdering av 
stemningsleie. Eksekutiv svikt, f.eks. etter hjerneslag og ved fronto temporal  demens, kan være vanskelig å påvise med MMSE-NR. Skåre og 
kvalitativ utførelse kan over tid endre seg ved flere psykiatriske og somatiske sykdomstilstander og sykdomsfaser: av og til med bedre utførelse 
og skåre, som ved behandling av depresjon eller delirium, ev. dårligere, som ved progredierende demens. 
TL bør ha fått opplæring i bruk av MMSE-NR og kjenne til manualens innhold (se www. aldringoghelse.no). Gjennomføring som ikke er i tråd med 
retningslinjer for administrasjon, oppfølgende spørsmål og skåring, kan gi for høy eller lav skåre. Dette kan få betydning for  utredning, konklusjon, 
opp følging og  behandling. Følg derfor  standardisert  instruksjon under hver oppgave og overhold retningslinjer i manual og på testskjema. Har PAS 
lav norsk språklig  kompetanse og annet morsmål enn norsk, bruk fag utdannet tolk (ikke slektninger) og språktilpasset stimulusark på oppgave 18.
Utfør testing en-til-en uten pårørende til stede. Slå av mobil telefoner. Sørg for at PAS ved behov bruker briller/hørselshjelpemidler. Minn ev. på 
bruk  underveis. Unngå at PAS ser skåring og svaralternativer på skjema. Les uthevet tekst høyt, langsomt og tydelig. Still samtlige spørsmål, 
også om PAS har besvart oppgave ledd under tidligere stilte spørsmål. All instruksjon kan  gjentas med unntak av  spesifiserte  begrensninger 
på  oppgave 12 og 17. Ikke gi hint om hvordan oppgavene kan løses eller om svar er rett eller galt. Skriv  ord rett ned svar på hvert spørsmål. 
PAS kan på eget initiativ korrigere svar underveis. Ved flere svar på et spørsmål må PAS velge hvilket svar som skal skåres. Dersom PAS har 
 vansker med å gi adekvate  muntlige svar, f.eks. ved afasi og andre talevansker, be PAS prøve å skrive svar på eget ark. Lar heller ikke dette seg 
 gjennomføre, bruk tilrettelagte MMSE-NR pekeark på aktuelle  orienteringsoppgaver. Sett kryss i ruten for «0» ved feil svar og i ruten for «1» ved 
rett svar. Gi aldri ½ poeng. Gir PAS utrykk for ikke å klare en eller flere av oppgavene, oppfordre  like vel til å gjøre et forsøk. Gjenta  oppfordring om 
 nødvendig. Er PAS ikke testbar på en  oppgave pga. ikke-kognitiv funksjonsbegrensning, notér  hvorfor og sett ring rundt ruten for «0». Inkluder 
likevel  oppgaven i totalskåren, da totalskåren skal angis i antall poeng av 30 mulige (det er f.eks. ikke tillatt å gi 23 av 25  poeng).
Ved retesting: For å redusere læringseffekt fra tidligere testing, bytt til riktig oppgavesett (ordsett og starttall) som spesifisert på oppgave 11–13. 
 Lavere alder og høyere  utdanning gir ofte bedre skåre, likeså  testing utført i  omgivelser som er velkjente for PAS pga. steds orienteringsoppgavene. 
 Notér faktorer som kan påvirke utførelse negativt, så som liten eller ingen skolegang, høy alder, svekket syn/manglende briller, svekket hørsel, 
dårlig dagsform, smerter, lav oppgaveinnsats, trettbarhet, afasi, lese- og skrivevansker, dyskalkuli, ikke-kognitiv funksjonsbegrensning, skriving/ 
tegning med  ikke-dominant hånd (f.eks. ved lammelse), rusmidler (inkl. alkohol), akutt  somatisk sykdom, depresjon, lav norsk språklig  kompetanse, 
stress og test angst. Legemiddeleffekter kan tidvis påvirke resultat negativt/positivt og krever egen vurdering. Total skåre alene gir ikke  informasjon 
om spesi fikke kognitive svikt områder som kan være  diagnostisk og klinisk relevante. Journalfør derfor også påfallende utførelse (lang  tidsbruk, 
mange korrigeringer o.l.), og hvilke oppgaver PAS ikke får til. Skåringsprofil og  kvalitativ vurdering av utførelse kan i tillegg gi  informa sjon om 
kognitive restressurser og kompen serende mestrings strategier som kan være nyttige for  tilrettelegging av  aktivitet og samhandling. 
Pasient (PAS)/fødselsdato:   Språk/tolk:    
Skolegang/utdanning/antall år:   Yrke:   
Hørsel/høreapparat:   Syn/briller:      
Testleder (TL):   Dato/kl:   Teststed:   
Er PAS testet med MMSE-NR før?                         Når/hvor/oppgavesett nr./skåre: 
Ja  Nei  Usikker 
Ja  Nei  Usikker 
Vurderer du som TL at samarbeid/motivasjon/testinnsats var uten anmerkning?
Vurderer du som TL at oppmerksomhet/bevissthetsnivå/våkenhet var uten anmerkning?
Vurderes ikke resultat som valid/gyldig, angi årsak(er):  
Merknader (atferd, bruk av pekeark, legemidler [inkl. dårlig legemiddeletterlevelse] som kan påvirke kognitiv funksjon, glemt briller/høreapparat e.l.): 
Basert på:  Folstein, M.F., Folstein, S.E. & McHugh, P.R. (1975). “Mini-Mental State”: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198. 
Engedal, K., Haugen, PK., Gilje, K. & Laake, P. (1988). Efficacy of short mental tests in the detection of mental impairment in old age. Compr Gerontol A, 2, 87-93.  























Skåring MMSE-NR3. Journalfør oppgavesett (ordsett og starttall oppgave 11–13) brukt i dag:  1     2     3     4     5 
Orientering (oppgave 1–10) /10
Umiddelbar gjenkalling (oppgave 11) /3
Hoderegning (oppgave 12) /5
Utsatt gjenkalling (oppgave 13) /3
Språk og praksis  (oppgave 14–19) /8
Figurkopiering (oppgave 20) /1
Total poengskåre /30
KOMMENTARER TIL SPESIFIKKE OPPGAVELEDD:
©Aldring og helse, 2018 
ISBN 978-82-8061-555-8
Fortsett med å trekke fra 7, 
helt til jeg sier stopp
Start med spørsmålet: Synes du hukommelsen din er blitt dårligere nå enn den var tidligere?   
Jeg skal nå stille deg noen spørsmål som vi bruker for bl.a. å undersøke hukommelsen. Svar så nøyaktig du kan. 
ORIENTERING 
Prøv å unngå at PAS bruker ledetråder: ser ut av vindu (årstid, måned, sted, etasje), bruker kalender, avis, innkallingsbrev (årstall,  
måned, ukedag, dato, sted), sjekker dato på klokke, mobiltelefon e.l. På oppgave 8 og 9, sett ring rundt valgt stedsalternativ.
1. Hva er din fødselsdato? Dag, måned og år må være rett for poeng      0   1 
(Sa PAS kun deler av sin fødselsdato, si: Si hele fødselsdatoen med dag, måned og år.)
2. Hvor gammel er du? (Sier PAS kun fødselsdato, si: Jeg mente, hvor mange år er du?)      0   1 
3. Hvilket årstall har vi nå? Gi kun poeng for fullt årstall med 4 sifre      0   1 
(Sa PAS kun siste 2 sifre, si: Si hele årstallet med alle tall. Hva heter det mer enn… [gjenta sifrene PAS sa]?) 
4. Hvilken årstid har vi nå? Ta hensyn til vær og geografiske forhold ved skåring (se manual)      0   1 
5. Hvilken måned har vi nå? Gi kun poeng for rett navn på måned, ikke for nummer på måned     0   1 
6. Hvilken dag har vi i dag? Gi kun poeng for rett navn på ukedag      0   1 
7. Hvilken dato har vi i dag? Gi poeng dersom dato for dag er rett, selv om måned eller år er feil      0   1   
8. Hvilken by/kommune/bygd (e.l.) er vi i (eller: er vi like i nærheten av) nå?      0   1 
9. Hva heter dette stedet/sykehuset/sykehjemmet/legekontoret (e.l.)? (eller: Hvor er vi nå?)      0   1 
10. I hvilken etasje er vi nå? Still spørsmålet selv der bygg kun har én etasje      0   1 
Avhengig av hvilken inngang PAS brukte, vil noen bygg i skrånende terreng kunne ha flere poenggivende svar for samme etasje  
(f.eks. under-, 1. og 2. etasje). Gi også poeng om PAS med annet morsmål, i tråd med sitt språk, benevner norsk 1. etasje som  
grunnplan (stuen [dansk], ground floor [engelsk]), og tilsvarende for andre etasjer (norsk 2. etasje: 1. sal [dansk], first floor [engelsk]). 
UMIDDELBAR GJENKALLING
Bytt til riktig ordsett ved retesting for å redusere læringseffekt fra tidligere testing: 2. gang PAS testes bruk ordsett 2 (tak-banan-nål),  
3. gang bruk ordsett 3 (saft-lampe-båt) osv., 6. gang bruk ordsett 1 på nytt, 7. gang bruk ordsett 2 osv. Sett ring rundt dagens ordsett.
11. Jeg vil nå si 3 ord som du skal gjenta, etter at jeg har sagt alle 3. Disse skal du prøve å huske,  
for jeg kommer til å spørre deg om dem litt senere. 1 sek pause etter hvert innlæringsord.  
Ordene du skal gjenta er: ...................... (1 sek), ...................... (1 sek), ..................... (1 sek). Vær så god!
Repeter hele ordsettet inntil PAS gjentar alle 3 ord i samme forsøk. Maks 3 presentasjoner. Gi kun poeng for riktige ord etter  
1. presentasjon, også for lydlike ord (f.eks. pga. hørselsvansker: mål for nål, hatt for katt). Rekkefølgen PAS sier ordene i, 
 er uten betydning for skåring. Antall presentasjoner:  stk.
Ordsett (nr. 1–5) brukt i dag: 1 2 3 4 5
Ordene du skal gjenta er... Stol Tak Saft Katt Fly  0   1  
Ekorn Banan Lampe Avis Eple  0   1  
Tog Nal Bat Løk Sko  0   1 
Etter 3 gjenkalte ord eller 3 presentasjoner, si: Husk disse ordene, for jeg vil spørre deg om hvilke de er litt senere.
HODEREGNING
Bytt til riktig starttall ved retesting: 2. gang bruk 50 osv., 6. gang bruk 80 på nytt, 7. gang 50 osv. PAS får ikke bruke blyant og papir,  
men kan på eget initiativ telle på fingrene. Gi poeng når svar er minus 7 fra forrige tall, uavhengig av om forrige svar var rett eller galt. 
12. Nå litt hoderegning. Hva er ........ minus 7? Før 1. subtraksjon (å trekke 7 fra starttallet) kan all instruksjon gjentas. 
(Gir PAS uttrykk for ikke å beherske hoderegning, oppfordre likevel til å gjøre et forsøk.) Rett etter tallsvaret, si : Fortsett  
med å trekke fra 7, helt til jeg sier stopp. Etter 1. subtraksjon kan kun instruksjon om å trekke fra 7 gjentas, men det er  
ikke lenger tillatt å informere om starttallet og heller ikke om hvilket tall PAS var kommet til. Etter 2. subtraksjon er det heller  
ikke tillatt å informere om hvor mye PAS skulle trekke fra (-7). Notér tallsvar og hvor mye PAS trakk fra (-), ev. la til (+).
Starttall (nr. 1–5) brukt i dag: 1 2 3 4 5
Starttall: Hva er .......... minus 7? 80 50 90 40 60
Ved behov, si: Og så videre.
Ved behov, si: Og så videre.
Ved behov, si: Og så videre.
73 43 83 33 53  0   1 
66 36 76 26 46  0   1 
59 29 69 19 39  0   1 
52 22 62 12 32  0   1 
45 15 55 5 25  0   1 
Etter 5 subtraksjoner (eller færre tallsvar hvis oppgaven ikke fullføres), si: Fint, det holder. Tell nå nedover fra 100  
slik som dette: 100, 99, 98, osv. til jeg sier stopp. Vær så god! Etter ca. 30 sek, si: Fint, det holder. Bruk alltid  
oppgaven for å få lang nok tid med distraksjon for å sikre reell kartlegging av  langtidshukommelse fremfor arbeidshukommelse på  
oppgave 13. Distraksjonsoppgaven skåres ikke, men notér ev. vansker med å telle baklengs, da dette kan gi klinisk relevant informasjon.
-7 = 1 poeng
PAS trakk fra (-), 
ev. la til (+):
Ja  Nei  Usikker 
PAS tallsvar:
                                                                                                                                                                                   
FRASEREPETISJON
16. Gjenta ordrett denne frasen nå (si tydelig): «Aldri annet enn om og men». (Ved behov, si: Start nå.)  
Gi kun poeng når hele frasen gjentas korrekt etter 1. presentasjon med alle 6 ord i riktig rekkefølge. Godta dialektvarianter.  
Gjentar ikke PAS frasen korrekt, gi 0 poeng og si frasen inntil 2 ganger til. Antall presentasjoner:  stk. 
Aldri annet enn om og men  0   1 
BENEVNING
Ved testing og retesting bruk kun stimulusarkene i farger med skje og hammer, aldri andre objekter.  
Alternative poenggivende svar: ord med skje/skjei, f.eks. spiseskje/plastskjei, ord med sleiv,  
f.eks. grøtsleiv, ord med øse/ause, f.eks. grautause, ord med hammer, f.eks. snekkerhammer.
14. Hva heter dette? Vis stimulusarket, pek på skjeen  0   1  
15. Hva heter dette? Vis stimulusarket, pek på hammeren  0   1  
3-LEDDET KOMMANDO
Legg A4-arket på bordet nærmere TL enn PAS med kortsiden mot PAS. For å unngå at PAS starter før hele instruksjonen er gitt, 
legger TL sin hånd på arket til all instruksjon er gitt. 1 sek pause etter hvert ledd. Gi 1 poeng for hver riktig utførte delhandling. 
17. Hør godt etter, for jeg skal be deg gjøre 3 ting i en bestemt rekkefølge. Start først når all instruksjon er gitt.  
Er du klar? Gi instruksjon om alle delhandlingene samlet og kun én gang: Ta dette arket med kun én hånd (1 sek),  
brett arket på midten kun én gang, med én eller begge hender (1 sek), og gi arket til meg (1 sek). Vær så god!  
Tar arket med kun én hand  0   1  
Bretter arket pa midten kun én gang (med én/begge hender, brett trenger ikke være helt på midten)  0   1  
Gir arket til TL (gi også poeng om arket legges på bordet tydelig foran TL)  0   1  
LESNING
18. Nå vil jeg at du gjør det som står på arket. Vis stimulusarket mens instruksjon gis.
PAS må peke mot (eller ta på) ansiktet sitt for poeng. Peker PAS mot TL, gi 0 poeng. Peker ikke PAS mot noen/noe  
(ev. kun leser teksten høyt), gi instruksjon maks 2 ganger til, og poeng ved rett utførelse. Antall presentasjoner:  stk.           
Pek på ansiktet ditt (PAS kan bruke én eller begge hender)  0   1 
SETNINGSGENERERING
Legg skjemaet på neste side med pil (↓) mot PAS. Gi PAS en blyant.
19. Skriv en meningsfull setning* her. Pek på X på øvre del av skjemaet neste side  0   1   
Skriver PAS kun ett ord, f.eks. en imperativform som «Spis», et subjekt som «Snøvær» eller et egennavn, si: Skriv en  
hel setning. Skriver ikke PAS noe eller tidligere gitt setning/frase, f.eks. «Pek på ansiktet ditt», si: Skriv en setning du  
lager selv. Skriver ikke PAS noe nå heller, si: Skriv en setning om noe i dette rommet. *Kan være på norsk eller morsmål. 
For poeng må setningen gi mening, men trenger ikke ha objekt og tidvis ikke subjekt eller verb. Se manualeksempler. Stave- og gramma- 
tikalske feil er uten betydning for skåring. Gi poeng for spørresetning om kriterier ellers er innfridd. Ved mer enn én setning, skår beste.
FIGURKOPIERING
Legg figurarket riktig vei (med pil [↓] mot PAS) over øvre del av neste side (over setningen PAS skrev).  
Legg et viskelær ved siden av (skal ikke brukes som linjal). Figurarket skal forbli liggende riktig plassert til  
PAS er helt ferdig (dette er ikke en hukommelsesoppgave).
20. Kopier figuren så nøyaktig du kan her. Pek på nedre del av skjemaet neste side. 
Du kan bruke viskelær, men ikke som linjal. Ta deg god tid.   0   1  
Gi poeng når femkantene overlapper og danner en firkant: 5-4-5. Er 5-4-5  innfridd, er det uten betydning for skåring hvor de  
over lapper, om det er innbyrdes størrelsesforskjell mellom dem, rotert utførelse eller størrelsesforskjell mellom figur og kopi.  
Se manualeksempler. Er PAS misfornøyd med utførelse, og denne er feil (jf. 5-4-5), be PAS korrigere eller tegne figuren på nytt.  
Maks 3 forsøk. Skår beste forsøk. Er TL i tvil om poengkriterier (jf. 5-4-5) er innfridd, be PAS tegne figuren på nytt.
UTSATT GJENKALLING






Er PAS i tvil om et ord var med, be PAS gjøre et valg. Sier PAS rett ord, men så hevder at ordet likevel ikke var med, gi 0 poeng. Ved  
flere enn 3 ord be PAS velge hvilke 3 ord som skal være svaret, kun disse skåres. Rekkefølgen PAS sier ordene i, er uten betydning  
for skåring. Gi kun poeng for eksakt gjengitte ord fra dagens ordsett (både best. og ubest. form entall gir poeng).  Beslektet ord, målord  
i sammensatt ord, flertallsform, synonym, omskrivning: stoler, skip, pus, gnager, togbane, lokomotiv o.l. gir ikke poeng. Sa PAS lydlikt  
ord på umiddelbar gjenkalling (f.eks. pga. hørselsvansker: mål for nål, hatt for katt), og samme ord gjentas på utsatt gjenkalling, gi poeng.
Ordsett (nr. 1–5) brukt i dag: 1 2 3 4 5
Stol Tak Saft Katt Fly  0   1  
Ekorn Banan Lampe Avis Eple  0   1 
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